INNOVATE (VATE) 10-Q 2 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-35210
Entity Registrant Name	INNOVATE CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	54-1708481
Entity Address, Address Line One	295 Madison Avenue
Entity Address, Address Line Two	12th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	235-2690
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		78,355,954
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001006837
Current Fiscal Year End Date	--12-31
Common Stock, par value $0.001 per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	VATE
Security Exchange Name	NYSE
Preferred Stock Purchase Rights
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
Security Exchange Name	NYSE
No Trading Symbol	true

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Cost of revenue	364.6	339.7	1,069.5	688.4
Gross profit	58.4	55.1	158.5	122
Operating expenses:
Selling, general and administrative	45.6	44.3	130.3	120.9
Depreciation and amortization	6.8	8.9	20.6	17.6
Other operating (income) loss	(0.6)	0.8	0.7	1
Income (loss) from operations	6.6	1.1	6.9	(17.5)
Other (expense) income:
Interest expense	(13.3)	(12.8)	(38.4)	(46.6)
Loss on early extinguishment or restructuring of debt	0	(0.1)	0	(12.5)
Loss from equity investees	(1.1)	(2.9)	(2.1)	(4.8)
Other (expense) income, net	(0.9)	0.6	0.5	4.4
Loss from continuing operations before income taxes	(8.7)	(14.1)	(33.1)	(77)
Income tax benefit (expense)	2	(0.1)	(1.6)	(3.8)
Loss from continuing operations	(6.7)	(14.2)	(34.7)	(80.8)
Loss from discontinued operations (including net loss on disposal of $200.3 million and $159.9 million for the three and nine months ended September 30, 2021, respectively)	0	(200.3)	0	(149.9)
Net loss	(6.7)	(214.5)	(34.7)	(230.7)
Net loss attributable to noncontrolling interest and redeemable noncontrolling interest	1.3	2.6	4.5	7.9
Net loss attributable to INNOVATE Corp.	(5.4)	(211.9)	(30.2)	(222.8)
Less: Preferred dividends and deemed dividends from conversions	1.2	1.1	3.6	1.7
Net loss attributable to common stock and participating preferred stockholders	$ (6.6)	$ (213)	$ (33.8)	$ (224.5)
Loss per common share - continuing operations
Basic (in usd per share)	$ (0.09)	$ (0.16)	$ (0.44)	$ (0.98)
Diluted (in usd per share)	(0.09)	(0.16)	(0.44)	(0.98)
Loss per common share - discontinued operations
Basic (in usd per share)	0	(2.59)	0	(1.94)
Diluted (in usd per share)	0	(2.59)	0	(1.94)
Loss per share - Net loss attributable to common stock and participating preferred stockholders
Basic (in usd per share)	(0.09)	(2.75)	(0.44)	(2.92)
Diluted (in usd per share)	$ (0.09)	$ (2.75)	$ (0.44)	$ (2.92)
Weighted average common shares outstanding:
Basic (in shares)	77.6	77.2	77.5	77
Diluted (in shares)	77.6	77.2	77.5	77

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Loss on sale of subsidiary				$ (159.9)
Discontinued Operations
Loss on sale of subsidiary	$ 0	$ (200.3)	$ 0	$ (159.9)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (6.7)	$ (214.5)	$ (34.7)	$ (230.7)
Other comprehensive loss
Foreign currency translation adjustment, net of tax	(2)	(1.2)	(3.8)	(2.4)
Unrealized loss on available-for-sale securities, net of tax	0	0	0	(57.7)
Dispositions	0	(334)	0	(334)
Other comprehensive loss	(2)	(335.2)	(3.8)	(394.1)
Comprehensive loss	(8.7)	(549.7)	(38.5)	(624.8)
Comprehensive loss attributable to noncontrolling interests and redeemable noncontrolling interests	1.5	2.6	4.8	8
Comprehensive loss attributable to INNOVATE Corp.	$ (7.2)	$ (547.1)	$ (33.7)	$ (616.8)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 25.8	$ 45.5
Accounts receivable, net	327.9	247.1
Contract assets	156	118.6
Inventory	20.7	17
Restricted cash	0.4	2
Assets held for sale	0	1.5
Other current assets	13.5	10.9
Total current assets	544.3	442.6
Investments	57.7	56
Deferred tax asset	2.7	3
Property, plant and equipment, net	168	169.9
Goodwill	126.8	127.4
Intangibles, net	194.3	208.4
Other assets	71.4	73.3
Total assets	1,165.2	1,080.6
Current liabilities
Accounts payable	213	179.2
Accrued liabilities	88.2	93.4
Current portion of debt obligations	81.4	69.5
Contract liabilities	95.4	79.1
Other current liabilities	20.1	18.3
Total current liabilities	498.1	439.5
Deferred tax liability	10.2	9.1
Debt obligations	627.9	556.8
Other liabilities	57.6	63.3
Total liabilities	1,193.8	1,068.7
Commitments and contingencies
Temporary equity
Preferred stock	17.9	18.8
Redeemable noncontrolling interest	45	49.3
Total temporary equity	62.9	68.1
Stockholders’ deficit
Common stock, $0.001 par value Shares authorized: 160,000,000 as of both September 30, 2022 and December 31, 2021 Shares issued: 79,784,214 and 79,225,964 as of September 30, 2022 and December 31, 2021, respectively Shares outstanding: 78,394,998 and 77,836,748 as of September 30, 2022 and December 31, 2021, respectively	0.1	0.1
Additional paid-in capital	330.2	330.6
Treasury stock, at cost: 1,389,216 shares as of both September 30, 2022 and December 31, 2021	(5.2)	(5.2)
Accumulated deficit	(446.4)	(416.2)
Accumulated other comprehensive income	2.9	6.4
Total INNOVATE Corp. stockholders’ deficit	(118.4)	(84.3)
Noncontrolling interest	26.9	28.1
Total stockholders’ deficit	(91.5)	(56.2)
Total liabilities, temporary equity and stockholders’ deficit	$ 1,165.2	$ 1,080.6

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	160,000,000	160,000,000
Common stock, shares issued (in shares)	79,784,214	79,225,964
Common stock, shares outstanding (in shares)	78,394,998	77,836,748
Treasury stock, common shares (in shares)	1,389,216	1,389,216

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($) shares in Millions, $ in Millions	Total	Preferred stock and fixed maturities	Total INNOVATE Stockholders' Equity (Deficit)	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Preferred stock and fixed maturities	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Non- controlling Interest	Temporary Equity	Temporary Equity Preferred stock and fixed maturities
Beginning balance (in shares) at Dec. 31, 2020				76.7
Beginning balance at Dec. 31, 2020	$ 600.2		$ 559.8	$ 0.1	$ 355.7		$ (4.2)	$ (188.7)	$ 396.9	$ 40.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	1.7		1.7		1.7
Fair value adjustment to redeemable noncontrolling interest	(0.3)		(0.3)		(0.3)
Taxes paid in lieu of shares issued for share-based compensation	(1)		(1)				(1)
Preferred stock dividend	(1.4)		(1.4)		(1.4)
Issuance of common stock (in shares)				1.1
Issuance of common stock	0.7		0.7		0.7
Purchase of preferred stock by subsidiary	(0.3)		(0.3)		(0.3)
Transactions with noncontrolling interests	(31.3)		(21.6)		(21.6)					(9.7)	$ 9.4
Other	(3.3)		(3.3)		(3.3)
Net (loss) income	(225.9)		(222.8)					(222.8)		(3.1)
Other comprehensive loss	(393.8)		(393.7)						(393.7)	(0.1)
Ending balance (in shares) at Sep. 30, 2021				77.8
Ending balance at Sep. 30, 2021	(54.7)		(82.2)	$ 0.1	331.2		(5.2)	(411.5)	3.2	27.5
Beginning balance at Dec. 31, 2020											15.7
Temporary Equity
Fair value adjustment to redeemable noncontrolling interest											0.4
Issuance of preferred stock and nonredeemable controlling interest	40.9	$ 19.1
Redemption of preferred shares											(10.4)
Transactions with noncontrolling interests	(31.3)		(21.6)		(21.6)					(9.7)	9.4
Net loss											(4.8)
Ending balance at Sep. 30, 2021											70.3
Beginning balance (in shares) at Jun. 30, 2021				77.8
Beginning balance at Jun. 30, 2021	511.5		488.3	$ 0.1	354.8		(5.2)	(199.6)	338.2	23.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	0.4		0.4		0.4
Preferred stock dividend	(1.1)		(1.1)		(1.1)
Purchase of preferred stock by subsidiary	(0.1)		(0.1)		(0.1)
Transactions with noncontrolling interests	(17.1)		(22.4)		(22.4)					5.3	5.6
Other	(0.4)		(0.4)		(0.4)
Net (loss) income	(212.9)		(211.9)					(211.9)		(1)
Other comprehensive loss	(335)		(335)						(335)
Ending balance (in shares) at Sep. 30, 2021				77.8
Ending balance at Sep. 30, 2021	(54.7)		(82.2)	$ 0.1	331.2		(5.2)	(411.5)	3.2	27.5
Beginning balance at Jun. 30, 2021											6.2
Temporary Equity
Fair value adjustment to redeemable noncontrolling interest											0.1
Issuance of preferred stock and nonredeemable controlling interest	40.9	19.1
Transactions with noncontrolling interests	(17.1)		(22.4)		(22.4)					5.3	5.6
Net loss	(1.6)
Ending balance at Sep. 30, 2021											70.3
Beginning balance (in shares) at Dec. 31, 2021				77.8
Beginning balance at Dec. 31, 2021	(56.2)		(84.3)	$ 0.1	330.6		(5.2)	(416.2)	6.4	28.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	1.7		1.7		1.7
Fair value adjustment to redeemable noncontrolling interest	0.1		0.1		0.1
Stock dividends and accretion	(3)		(1.7)		(1.7)					(1.3)	(0.9)
Issuance of common stock (in shares)				0.6
Transactions with noncontrolling interests	(0.3)		0.1		0.1					(0.4)	0.2
Other	0.3		0.3		0.3
Net (loss) income	(29.4)		(30.2)					(30.2)		0.8
Other comprehensive loss	(3.8)		(3.5)						(3.5)	(0.3)
Ending balance (in shares) at Sep. 30, 2022				78.4
Ending balance at Sep. 30, 2022	(91.5)		(118.4)	$ 0.1	330.2		(5.2)	(446.4)	2.9	26.9
Beginning balance at Dec. 31, 2021	68.1										68.1
Temporary Equity
Fair value adjustment to redeemable noncontrolling interest											(0.1)
Issuance of preferred stock and nonredeemable controlling interest		$ (0.9)	(0.9)			$ (0.9)						$ 0.9
Stock dividends and accretion	(3)		(1.7)		(1.7)					(1.3)	(0.9)
Transactions with noncontrolling interests	(0.3)		0.1		0.1					(0.4)	0.2
Net loss											(5.3)
Ending balance at Sep. 30, 2022	62.9										62.9
Beginning balance (in shares) at Jun. 30, 2022				78.4
Beginning balance at Jun. 30, 2022	(84.1)		(110.7)	$ 0.1	330.7		(5.2)	(441)	4.7	26.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	0.4		0.4		0.4
Stock dividends and accretion	(0.9)		(0.9)		(0.9)						(0.3)
Transactions with noncontrolling interests	(0.2)									(0.2)	0.1
Net (loss) income	(4.8)		(5.4)					(5.4)		0.6
Other comprehensive loss	(1.9)		(1.8)						(1.8)	(0.1)
Ending balance (in shares) at Sep. 30, 2022				78.4
Ending balance at Sep. 30, 2022	(91.5)		(118.4)	$ 0.1	330.2		$ (5.2)	$ (446.4)	$ 2.9	26.9
Beginning balance at Jun. 30, 2022											65
Temporary Equity
Stock dividends and accretion	(0.9)		$ (0.9)		$ (0.9)						(0.3)
Transactions with noncontrolling interests	(0.2)									$ (0.2)	0.1
Net loss											(1.9)
Ending balance at Sep. 30, 2022	$ 62.9										$ 62.9

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (34.7)	$ (230.7)
Less: Loss from discontinued operations, net of tax	0	(149.9)
Net loss, excluding loss from discontinued operations	(34.7)	(80.8)
Adjustments to reconcile net loss to cash used in continuing operating activities
Share-based compensation expense	1.7	1.7
Depreciation and amortization	31.8	26
Amortization of deferred financing costs and debt discount	3.2	9.4
Loss on extinguishment of debt	0	12.5
Loss from equity investees	2.1	4.8
Asset impairment expense	2	2.7
Deferred income taxes	1.2	1.1
Other operating activities, net	(2.7)	(5)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable	(77)	(78.3)
Contract assets	(37.4)	(27.2)
Other current assets	(1.1)	(0.4)
Inventory	(3.7)	(1.8)
Other assets	10.2	7.9
Accounts payable	31.5	65.7
Accrued liabilities	(5.6)	6.7
Contract liabilities	16.3	16.8
Other current liabilities	(4.9)	(2.8)
Other liabilities	(5.1)	(7.1)
Cash used in continuing operating activities	(72.2)	(48.1)
Cash provided by discontinued operating activities	0	33.5
Cash used in operating activities	(72.2)	(14.6)
Cash flows from investing activities
Purchase of property, plant and equipment	(16.3)	(15)
Proceeds from disposal of property, plant and equipment	1.9	12.5
Loan to equity method investee	(4.5)	0
Cash received from dispositions, net of cash disposed	0	74
Extraordinary dividend received in business disposition	0	62.5
Cash paid for acquisitions, net of cash acquired	0	(128.5)
Other investing activities	0.6	0.9
Cash (used in) provided by continuing investing activities	(18.3)	6.4
Cash used in discontinued investing activities	0	(221.3)
Cash used in investing activities	(18.3)	(214.9)
Cash flows from financing activities
Proceeds from debt obligations, net of deferred financing costs	9.9	452.3
Principal payments on debt obligations	(23.7)	(454.8)
Proceeds from line of credit, net of deferred financing costs	176.8	156
Payments on line of credit	(85.1)	(78.5)
Redemption of preferred stock	0	(10.4)
Cash received by subsidiary to issue preferred stock	0	10.5
Transactions with noncontrolling interests	0	(9.5)
Dividend payments	(3.9)	(2)
Other financing activities	(0.8)	(1.4)
Cash provided by continuing financing activities	73.2	62.2
Cash used in discontinued financing activities	0	(7.6)
Cash provided by financing activities	73.2	54.6
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(2.5)	(1.7)
Net decrease in cash and cash equivalents, including restricted cash and cash classified within assets held for sale	(19.8)	(176.6)
Less: Net decrease in cash and cash equivalents from discontinued operations	0	(195.4)
Net change in cash, cash equivalents and restricted cash	(19.8)	18.8
Cash, cash equivalents and restricted cash, beginning of period	47.5	45.3
Cash, cash equivalents and restricted cash, end of period	$ 27.7	$ 64.1

Organization and Business

Organization and Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. Organization and Business INNOVATE Corp. ("INNOVATE" and, together with its consolidated subsidiaries, the "Company", "we" and "our") is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. We seek to grow these businesses so that they can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. While the Company generally intends to acquire controlling equity interests in its operating subsidiaries, the Company may invest to a limited extent in a variety of noncontrolling equity interest positions or debt instruments. The Company’s shares of common stock trade on the NYSE under the symbol "VATE". The Company currently has three reportable segments, plus our Other segment, based on management’s organization of the enterprise: Infrastructure, Life Sciences, Spectrum, and Other which includes businesses that do not meet the separately reportable segment thresholds. 1. Our Infrastructure segment is comprised of DBM Global Inc. ("DBMG") and its wholly-owned subsidiaries. DBMG is a fully integrated industrial construction, structural steel and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services and also fabricates trusses and girders and specializes in the fabrication and erection of large-diameter water pipe and water storage tanks, as well as 3-D Building Information Modeling (“BIM”) and detailing. DBMG provides these services on commercial, industrial, and infrastructure construction projects such as high- and low-rise buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills and power plants. Through GrayWolf Industrial Inc. ("GrayWolf"), DBMG provides integrated solutions for digital engineering, modeling and detailing, construction, heavy equipment installation and facility services including maintenance, repair, and installation to a diverse range of end markets. Through Aitken Manufacturing, Inc., DBMG manufactures pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators and a variety of customized products. Through Banker Steel Holdco, LLC ("Banker Steel"), DBMG provides full-service fabricated structural steel and erection services primarily for the East Coast and Southeast commercial and industrial construction market, in addition to full design-assist services. The Company maintains an approximately 91% controlling interest in DBMG. 2. Our Life Sciences segment is comprised of Pansend Life Sciences, LLC ("Pansend"), its subsidiaries and equity method investments. Pansend maintains controlling interests of approximately 80% in Genovel Orthopedics, Inc. ("Genovel"), which seeks to develop products to treat early osteoarthritis of the knee and approximately 56% in R2 Technologies, Inc. ("R2"), which develops aesthetic and medical technologies for the skin. Pansend also invests in other early stage or developmental stage healthcare companies including an approximately 47% interest in MediBeacon Inc. ("MediBeacon"), a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement, potentially enabling real-time, direct monitoring of kidney function, and an approximately 26% interest in Triple Ring Technologies, Inc ("Triple Ring"), a science and technology co-development company. 3. Our Spectrum segment is comprised of HC2 Broadcasting Holdings Inc. ("Broadcasting") and its subsidiaries. Broadcasting strategically acquires and operates over-the-air broadcasting stations across the United States. In addition, Broadcasting, through its wholly-owned subsidiary, HC2 Network Inc. ("Network"), operates Azteca America, a Spanish-language broadcast network offering high quality Hispanic content to a diverse demographic across the United States. The Company maintains a 98% controlling interest in Broadcasting and maintains a controlling interest of approximately 77%, inclusive of approximately 10% proxy and voting rights from minority holders of DTV America Corporation ("DTV"). 4. Our Other segment represents all other businesses or investments that do not meet the definition of a segment individually or in the aggregate. Included in the Other segment is the former Marine Services segment, which includes its holding company, Global Marine Holdings, LLC ("GMH"), in which the Company maintains approximately 73% controlling interest. GMH results include the current and prior year equity investment in HMN Technologies Co., Ltd. (“HMN”), its 19% equity method investment, and the discontinued operations of Global Marine Systems Limited ("GMSL"). Also included in the Other segment is the discontinued operations of Beyond6, Inc. ("Beyond6"), and Continental Insurance Group ("CIG").

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries and all other subsidiaries over which the Company exerts control. All intercompany profits, transactions and balances have been eliminated in consolidation. For the three and nine months ended September 30, 2022, the results of DBMG, Pansend, Genovel, R2, Broadcasting, and GMH have been consolidated into the Company’s results based on guidance from the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" 810, Consolidation) . The remaining interests not owned by the Company are presented as a noncontrolling interest component of total equity. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of such information. All such adjustments are of a normal recurring nature. Certain information and note disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been condensed or omitted in these interim financial statements pursuant to such rules and regulations. Certain prior amounts have been reclassified or combined to conform to the current year presentation. These interim financial statements should be read in conjunction with the Company’s annual audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 9, 2022. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results for any subsequent periods or the entire fiscal year ending December 31, 2022. Use of Estimates and Assumptions The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions used. Liquidity At this time, we believe that we will be able to continue to meet our liquidity requirements and fund our fixed obligations (such as debt service and operating leases) and other cash needs for our operations for at least the next twelve months from the issuance of the Condensed Consolidated Financial Statements through a combination of available cash and distributions from our subsidiaries. The ability of INNOVATE’s subsidiaries to make distributions to INNOVATE is subject to numerous factors, including restrictions contained in each subsidiary’s financing agreements, availability of sufficient funds at each subsidiary and the approval of such payment by each subsidiary’s board of directors, which must consider various factors, including general economic and business conditions, tax considerations, strategic plans, financial results and condition, expansion plans, any contractual, legal or regulatory restrictions on the payment of dividends, and such other factors each subsidiary’s board of directors considers relevant. Although the Company believes, to the extent needed, that it will be able to raise additional debt or equity capital, refinance indebtedness or preferred stock, enter into other financing arrangements or engage in asset sales and sales of certain investments sufficient to fund any cash needs that we are not able to satisfy with the funds on hand or expected to be provided by our subsidiaries, there can be no assurance that it will be able to do so on terms satisfactory to the Company, if at all. Such financing options, if pursued, may also ultimately have the effect of negatively impacting our liquidity profile and prospects over the long-term and dilute holders of common stock. Our ability to sell assets and certain of our investments to meet our existing financing needs may also be limited by our existing financing instruments. In addition, the sale of assets or the Company’s investments may also make the Company less attractive to potential investors or future financing partners. COVID-19 There are many uncertainties regarding the current coronavirus ("COVID-19") pandemic, and the Company continues to closely monitor the impact of the COVID-19 pandemic, including the effectiveness of the vaccine programs, on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, business partners and distribution channels and any potential prolonging or worsening of the pandemic due to COVID-19 variants. We are unable to predict the impact that COVID-19 will have on the Company's financial position and operating results due to numerous uncertainties. However, as the pandemic continues, it may have an adverse effect on the Company’s results of operations, financial condition, or liquidity. COVID-19 has continued to cause supply chain challenges related to labor shortages and supply chain disruptions, which may create significant delays in our ability to complete projects or deliver products. The receipt of material from impacted areas has been slowed or disrupted and our suppliers are expected to face similar challenges in fulfilling or placing orders, including jurisdictions such as Greater China which continue to have government-mandated lockdowns. In addition, reductions in the number of ocean carrier voyages, ocean freight capacity issues, congestion at major international gateways and other economic factors continue to persist worldwide due to COVID-19 and worldwide supply impacts as there is much greater demand for shipping and reduced capacity and equipment, which has resulted in recent price increases per shipping container. In addition, in the United States, trucking costs have risen dramatically due to driver shortages and increased labor costs, as well as new federal and state safety, environmental and labor regulations. These changes may disrupt our supply chain, which may result in a delay in the completion of our projects and cause us to incur significant additional costs. Although we may attempt to pass on certain of these increased costs to our customers, we may not be able to pass all of these cost increases on to our customers. As a result, our margins may be adversely impacted by such cost increases. These supply chain disruptions and transportation challenges could have a material adverse effect on our results of operations or financial condition. The Company expects to continue to assess the evolving impact of the COVID-19 pandemic. Accounting Pronouncements Adopted in the Current Year There were no new accounting pronouncements adopted during the nine months ended September 30, 2022. Accounting Pronouncements to be Adopted in 2023 Credit Loss Standard In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) , Measurement of Credit Losses on Financial Instruments . This new standard and its related amendments change the impairment model for most financial assets that are measured at amortized cost and certain other instruments, including trade receivables and contract assets, from an incurred loss model to an expected loss model and adds certain new required disclosures. Under the expected loss model, entities will recognize estimated credit losses over the entire contractual term of the instrument rather than delaying recognition of credit losses until it is probable the loss has been incurred. The Company is required to adopt Topic 326 on January 1, 2023. The Company is currently evaluating the application of the new standard and does not expect the adoption to have a significant impact on the Company's financial statements. Subsequent Events ASC 855, Subsequent Events requires the Company to evaluate events that occur after the balance sheet date as of which the financial statements are issued, and to determine whether adjustments to or additional disclosures in the financial statements are necessary. See Note 25. Subsequent Events for any subsequent events.

Revenue and Contracts in Proces

Revenue and Contracts in Process	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue and Contracts in Process	3. Revenue and Contracts in Process Revenue from contracts with customers consist of the following (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue Infrastructure $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 Life Sciences 1.2 1.6 3.0 2.8 Spectrum 9.1 10.2 28.0 31.3 Total revenue $ 423.0 $ 394.8 $ 1,228.0 $ 810.4 Accounts receivables, net, from contracts with customers consist of the following (in millions): September 30, December 31, Accounts receivables with customers Infrastructure $ 313.9 $ 226.8 Life Sciences 0.8 0.3 Spectrum 7.1 9.4 Total accounts receivables with customers $ 321.8 $ 236.5 Contract assets and contract liabilities and recognized earnings consist of the following (in millions): September 30, December 31, Costs incurred on contracts in progress $ 2,098.3 $ 2,161.5 Estimated earnings 343.5 316.4 Contract revenue earned on uncompleted contracts 2,441.8 2,477.9 Less: progress billings 2,381.2 2,438.4 $ 60.6 $ 39.5 The above is included in the accompanying consolidated balance sheets under the following line items: Contract assets $ 156.0 $ 118.6 Contract liabilities (95.4) (79.1) $ 60.6 $ 39.5 Infrastructure Segment The following table disaggregates DBMG's revenue by market (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Commercial $ 187.3 $ 207.0 $ 643.9 $ 343.3 Industrial 96.3 92.9 270.5 207.9 Healthcare 36.0 17.1 93.3 37.2 Convention 55.5 23.4 97.2 51.7 Transportation 15.0 16.0 32.9 40.0 Leisure 7.9 4.8 17.7 16.5 Government 10.9 15.9 27.4 54.6 Other 3.7 5.9 13.7 25.1 Total revenue from contracts with customers 412.6 383.0 1,196.6 776.3 Other revenue 0.1 — 0.4 — Total Infrastructure segment revenue $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 Contract assets and contract liabilities consisted of the following (in millions): September 30, December 31, Cost in excess of billings $ 85.4 $ 68.3 Conditional retainage 70.6 50.3 Contract assets $ 156.0 $ 118.6 Billings in excess of costs $ (152.7) $ (137.6) Conditional retainage 57.3 58.5 Contract liabilities $ (95.4) $ (79.1) The change in contract assets is a result of the recording of $171.4 million of contract assets driven by new commercial projects, offset by $134.0 million of contract assets transferred to receivables from contract assets recognized at the beginning of the period. The change in contract liabilities is a result of periodic contract liabilities of $93.2 million driven largely by new commercial projects, offset by revenue recognized that was included in the contract liability balance at the beginning of the period in the amount of $76.9 million. Transaction Price Allocated to Remaining Unsatisfied Performance Obligations As of September 30, 2022, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions): Within One Year Within Five Years Total Commercial $ 409.7 $ 110.4 $ 520.1 Industrial 243.4 18.5 261.9 Transportation 332.9 97.6 430.5 Government 13.2 — 13.2 Leisure 6.6 — 6.6 Healthcare 418.9 108.9 527.8 Convention 132.0 8.0 140.0 Other 3.0 — 3.0 Remaining unsatisfied performance obligations $ 1,559.7 $ 343.4 $ 1,903.1 DBMG's remaining unsatisfied performance obligations increase with awards of new contracts and decrease as it performs work and recognizes revenue on existing contracts. DBMG includes a project within its remaining unsatisfied performance obligations at such time the project is awarded and agreement on contract terms has been reached. DBMG's remaining unsatisfied performance obligations include amounts related to contracts for which a fixed price contract value is not assigned when a reasonable estimate of total transaction price can be made. DBMG expects to recognize this revenue within the next thirty-six months. Remaining unsatisfied performance obligations include unrecognized revenues to be realized from uncompleted construction contracts. Although many of DBMG's contracts are subject to cancellation at the election of its customers, in accordance with industry practice, DBMG does not limit the amount of unrecognized revenue included within its remaining unsatisfied performance obligations due to the inherent substantial economic penalty that would be incurred by its customers upon cancellation. Life Sciences Segment The following table disaggregates the Life Sciences segment's revenue by type (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Systems and consumables revenue $ 1.2 $ 1.6 $ 3.0 $ 2.8 Total Life Sciences segment revenue $ 1.2 $ 1.6 $ 3.0 $ 2.8 Spectrum Segment The following table disaggregates the Spectrum segment's revenue by type (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Broadcast station $ 4.7 $ 4.7 $ 14.2 $ 13.6 Network advertising 3.4 4.2 10.7 13.7 Network distribution 0.8 0.8 2.2 2.5 Other 0.2 0.5 0.9 1.5 Total Spectrum segment revenue $ 9.1 $ 10.2 $ 28.0 $ 31.3 As of September 30, 2022, the transaction price allocated to remaining unsatisfied performance obligations consisted of $3.4 million of broadcast station revenues, $0.1 million of network advertising and $0.1 million of other revenues, of which $2.8 million is expected to be recognized within one year and $0.8 million is expected to be recognized within the next thirty-six months.

Accounts Receivable, Net

Accounts Receivable, Net	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Accounts Receivable, Net	4. Accounts Receivable, Net Accounts receivable, net consist of the following (in millions): September 30, December 31, Contracts in progress $ 313.9 $ 226.8 Unbilled retentions 0.4 0.4 Trade receivables 7.8 9.9 Other receivables 6.1 10.6 Allowance for doubtful accounts (0.3) (0.6) Total $ 327.9 $ 247.1

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory consists of the following (in millions): September 30, December 31, Raw materials and consumables $ 17.3 $ 14.3 Work in process 0.8 1.2 Finished goods 2.6 1.5 Total inventory $ 20.7 $ 17.0

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments The carrying values of the Company's investments were as follows (in millions): September 30, 2022 Measurement Alternative (1) Equity Fair Value Total Common stock $ — $ 2.9 $ — $ 2.9 Preferred stock and fixed maturities — 0.5 5.6 6.1 Put option 11.3 — — 11.3 Investment in securities — 37.4 — 37.4 Total $ 11.3 $ 40.8 $ 5.6 $ 57.7 December 31, 2021 Measurement Alternative (1) Equity Fair Value Total Common stock $ — $ 2.1 $ — $ 2.1 Preferred stock and fixed maturities 0.5 2.1 5.4 8.0 Put option 11.3 — — 11.3 Investment in securities — 34.6 — 34.6 Total $ 11.8 $ 38.8 $ 5.4 $ 56.0 (1) The Company accounts for its equity securities without readily determinable fair values under the measurement alternative election of ASC 321, whereby the Company can elect to measure an equity security without a readily determinable fair value, that does not qualify for the practical expedient to estimate fair value (net asset value), at its cost minus impairment, if any . Pansend accounts for MediBeacon's preferred stock as an equity method investment, inclusive of any fixed maturity securities issued by Pansend to MediBeacon. During the nine months ended September 30, 2022, Pansend issued MediBeacon a $4.5 million 8.0% convertible note due March 2025, increasing the total outstanding principal to $5.0 million. The increase in the net basis was partially offset by additional equity method losses recognized on MediBeacon. Equity Method Investments The Company's share of net loss from its equity method investments was $1.1 million and $2.9 million for the three months ended September 30, 2022 and 2021, respectively. The Company's share of net loss from its equity method investments totaled $2.1 million and $4.8 million for the nine months ended September 30, 2022 and 2021, respectively. The Company accounts for its Triple Ring equity method investment results on a one-month lag basis. The following tables provide summarized financial information for the Company's equity method investments (in millions): September 30, December 31, Assets $ 645.4 $ 604.5 Liabilities 530.4 481.5 Equity $ 115.0 $ 123.0 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Total revenues $ 149.8 $ 92.0 $ 359.1 $ 390.6 Gross profit $ 23.1 $ 14.4 $ 68.0 $ 58.7 Operating income (loss) $ 2.5 $ (7.1) $ 7.9 $ (6.2) Net income (loss) $ 0.1 $ (8.4) $ 6.9 $ (8.3)

Property, Plant & Equipment, Ne

Property, Plant & Equipment, Net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant & Equipment, Net	7. Property, Plant & Equipment, Net Property, plant and equipment, net, consists of the following (in millions): September 30, December 31, Equipment, furniture and fixtures, and software $ 192.1 $ 180.7 Building and leasehold improvements 44.8 43.0 Land 26.1 24.1 Construction in progress 9.3 8.9 Plant and transportation equipment 8.3 8.3 $ 280.6 $ 265.0 Less: Accumulated depreciation 112.6 95.1 Total $ 168.0 $ 169.9 Depreciation expense was $6.6 million and $7.8 million for the three months ended September 30, 2022 and 2021, respectively. These amounts included $3.9 million and $3.4 million of depreciation expense recognized within cost of revenue for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $19.3 million and $17.7 million for the nine months ended September 30, 2022 and 2021, respectively. These amounts included $11.2 million and $8.4 million of depreciation expense recognized within cost of revenue for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022 and December 31, 2021, the aggregate net book value of equipment under capital leases totaled $2.2 million and $0.2 million, respectively.

Goodwill and Intangibles, Net

Goodwill and Intangibles, Net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangibles, Net	8. Goodwill and Intangibles, Net Goodwill The carrying amount of goodwill by segment was as follows (in millions): Infrastructure Spectrum Total Balance at December 31, 2021 $ 106.0 $ 21.4 $ 127.4 Translation (0.6) — (0.6) Balance as of September 30, 2022 $ 105.4 $ 21.4 $ 126.8 Indefinite-lived Intangible Assets The carrying amount of indefinite-lived intangible assets was as follows (in millions): September 30, 2022 December 31, 2021 FCC licenses $ 106.4 $ 106.5 Total $ 106.4 $ 106.5 For the nine months ended September 30, 2022 and 2021, the Company recorded impairment charges of $0.1 million and $2.7 million, respectively, which is reflected in Other operating (income) loss, related to non-core FCC licenses which were sold or expired in order to bring their carrying value equal to the agreed upon sales price prior to the execution of the sale or expiration. Definite Lived Intangible Assets The gross carrying amounts and accumulated amortization of definite lived intangible assets by major intangible asset class were as follows (in millions): Weighted-Average Original Useful Life September 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trade names 14 years $ 25.4 $ (7.6) $ 17.8 $ 25.4 $ (6.3) $ 19.1 Customer relationships and contracts 11 years 87.5 (31.8) 55.7 87.7 (21.6) 66.1 Channel sharing arrangements 35 years 12.6 (1.4) 11.2 12.6 (1.1) 11.5 Other 12 years 4.1 (0.9) 3.2 8.5 (3.3) 5.2 Total $ 129.6 $ (41.7) $ 87.9 $ 134.2 $ (32.3) $ 101.9 For the nine months ended September 30, 2022, the Company recorded impairment charges to definite lived intangible assets of $1.5 million in Other operating (income) loss related to the impairment of the HC2 Network Program License Agreement ("PLA") due to a decline in performance. Amortization expense for definite lived intangible assets was $4.1 million and $4.5 million for the three months ended September 30, 2022 and 2021, respectively, and was included in Depreciation and amortization in our Condensed Consolidated Statements of Operations. Amortization expense for definite lived intangible assets was $12.5 million and $8.3 million for the nine months ended September 30, 2022 and 2021, respectively, and was included in Depreciation and amortization in our Condensed Consolidated Statements of Operations. Amortization Future estimated annual amortization expense for intangible assets is as follows (in millions): Estimated Amortization 2022 $ 4.1 2023 11.0 2024 7.4 2025 7.2 2026 6.9 Thereafter 51.3 Total $ 87.9

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	9. Acquisitions Infrastructure Segment Banker Steel Acquisition On March 15, 2021, the Company announced that DBMG entered into an agreement to acquire 100% of Banker Steel Holdco LLC ("Banker Steel") for $145.0 million, which closed on May 27, 2021. The acquisition was financed with $64.1 million from a partial draw on a new $110.0 million revolving credit facility, $49.6 million of sellers' notes, $6.3 million of assumed debt of Banker Steel, and $25.0 million in cash received from INNOVATE in the settlement of certain intercompany balances. Banker Steel, which is included in the Company's Infrastructure segment, provides full-service fabricated structural steel and erection services primarily for the East Coast and Southeast commercial and industrial construction market, in addition to full design-assist services. Banker Steel consists of six operating companies: Banker Steel Co., LLC; NYC Constructors, LLC; Memco LLC; Derr & Isbell Construction LLC; Innovative Detailing and Engineering Solutions; and Lynchburg Freight and Specialty LLC. Results of Operations and Unaudited Supplemental Pro Forma Information The following table presents the unaudited results of operations data for the nine months ended September 30, 2021 for Banker Steel from the date of acquisition (in millions): Nine Months Ended September 30, 2021 Revenue $ 153.8 Income from operations $ 7.3 Net income attributable to INNOVATE $ 4.5 The following table presents unaudited consolidated pro forma results of operations data as if the acquisition of Banker Steel had occurred at the beginning of the prior period. This information does not purport to be indicative of the actual results that would have occurred if the acquisitions had actually been completed on the date indicated, nor is it necessarily indicative of the future operating results or the financial position of the combined company (in millions): Nine Months Ended September 30, 2021 Revenue $ 1,007.9 Loss from operations $ (6.0) Net loss attributable to INNOVATE $ (214.5)

Dispositions, Deconsolidations

Dispositions, Deconsolidations and Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Dispositions, Deconsolidations and Discontinued Operations	10. Dispositions, Deconsolidations and Discontinued Operations Sale of CIG The sale of CIG closed on July 1, 2021 to Continental General Holdings LLC ("Continental"), an entity controlled by Michael Gorzynski, a former director of the Company who also serves as executive chairman of Continental since October 2020. Our previous segment incorporating CIG (the "Insurance segment"), which primarily consisted of a closed block of long-term care insurance, had a book value, inclusive of intercompany eliminations, at the time of the sale of $544.0 million, inclusive of $344.0 million of Accumulated other comprehensive income ("AOCI"). The carrying value of the Insurance segment at the time of sale excluded cash of $62.5 million and investments of $26.7 million which were distributed to the Company through an extraordinary dividend immediately prior to the sale. The extraordinary dividend was approved by our domestic regulator in connection with the approval of the sale. The amount included in AOCI was reversed from equity at the time of the sale and offset the loss recognized. While several factors impacted the fair value of the Insurance segment at the end of 2019, following discussions with our domestic regulator, changes in the asset management fee arrangement and expectations of future dividends primarily and ultimately resulted in the full impairment of the goodwill associated with the Insurance segment during the year ended December 31, 2019. While these factors did not have a major impact on the operations of the stand-alone business, they did have a significant impact on the economic benefit that could be realized by the Company. As a result of the factors described above, combined with the risks associated with the long-term care insurance industry, the Company exited the Insurance segment and sold the business resulting in a $200.8 million loss on the sale of CIG in the third quarter of 2021. On September 3, 2022, INNOVATE and Continental entered into a tax cooperation agreement permitting Continental General Insurance Company ("CGIC") to consolidate into INNOVATE's 2021 U.S. tax return for the six-month period INNOVATE owned CGIC, allowing CGIC to shield some of its income tax liability by utilizing a portion of INNOVATE's Net Operating Losses ("NOLs") while also converting a portion of INNOVATE's IRC Sec. 163(j) carryforward assets into NOLs. See Note 16. Income Taxes for additional information regarding income tax attributes. The net tax savings of $2.9 million on CGIC's income tax liability was split between CGIC and INNOVATE in accordance with the tax sharing agreement, which was executed on October 11, 2022. INNOVATE recognized a current income tax benefit of $2.9 million in the current period and expects to receive $1.2 million as a result of the tax sharing agreement during the fourth quarter of 2022. As CGIC is no longer a subsidiary of INNOVATE, the $1.7 million tax benefit to be received by CGIC tax share is treated as a deemed contribution, and INNOVATE recognizes an additional $1.7 million loss related to the previous sale of the subsidiary, through continuing operations. Sale of Beyond6 On December 31, 2020, the Company announced a plan to sell Beyond6 to an affiliate of Mercuria Investments US, Inc., pursuant to an Agreement and Plan of Merger (the "Merger Agreement") among Beyond6, Greenfill, Inc., a Delaware corporation ("Parent"), Greenfill Merger Inc., a newly-formed Delaware corporation and wholly-owned subsidiary of the Parent, and an affiliate of INNOVATE as the Stockholder Representative for the Beyond6 stockholders, for a total purchase price, net of Beyond6's debt and transaction expenses, customary purchase price adjustments and escrow arrangements, of approximately $106.5 million. Net proceeds received by INNOVATE at closing was cash consideration of approximately $70.0 million. The sale closed on January 15, 2021. During the first quarter of 2021, the Company recognized a $39.2 million gain on the sale. During the third quarter of 2021, as a result of releases of related escrows and hold backs, the Company recognized an additional $0.5 million gain on the sale. A portion of the proceeds from the sale of Beyond6 were used to repay $15.0 million of the then outstanding balance under the 6.75% line of credit with MSD PCOF Partners IX, LLC ("Revolving Credit Agreement") and repay $27.9 million of the Company's 2021 Senior Secured Notes. Sale of GMSL On January 30, 2020, the Company announced that, through its indirect subsidiary, GMH, in which the Company holds an approximately 73% controlling interest, the Company entered into a definitive agreement to sell 100% of the shares of GMSL to Trafalgar AcquisitionCo, Ltd. and an affiliate of J.F. Lehman & Company, LLC. The total base consideration was $250.0 million, subject to customary purchase price adjustments, working capital adjustments, and a potential earn-out of up to $12.5 million at such time, if any, if J.F. Lehman & Company, LLC and its investment affiliates achieve a specified multiple of their invested capital. The purchase price is subject to customary potential downward or upward post-closing adjustments based on net working capital, cash, unpaid transaction expenses, indebtedness and certain of the Company’s pre-closing paid capital expenditures. The Share Purchase Agreement contained customary representations, warranties and covenants for a transaction of this nature. The transaction closed on February 28, 2020. GMH received approximately $144.0 million of net proceeds from the sale, of which $36.8 million and $5.5 million were paid to noncontrolling interest holders and redeemable noncontrolling interest holders, respectively. INNOVATE received net proceeds of approximately $100.8 million. In connection with the closing of the transaction, the purchaser deposited (i) $1.25 million of the base price into an escrow fund for the purpose of securing certain indemnification obligations for losses payable in the first twelve months after closing and (ii) $1.91 million of the base price into an escrow fund for the purpose of securing a purchase price adjustment, if any, in favor of purchaser. Following the closing, the purchaser paid an amount equal to $2.4 million on the earlier of December 31, 2020 and the date on which a cash collateralized bonding facility was released. In the first quarter of 2020, the Company recorded a $39.3 million loss on the sale and recognized a $31.3 million of Accumulated other comprehensive loss, which was comprised of $17.2 million of actuarial losses on pension and $14.1 million of currency translation adjustments. During the fourth quarter of 2020, the Company recognized a gain on sale of $2.4 million as a result of the cash collateralized bonding facility release. During the first quarter of 2021, the Company recognized a gain of $1.2 million as a result of indemnity release. Discontinued Operations Reporting The results of Beyond6 and CIG and the related expenses directly attributable to the entities were reported as discontinued operations. The discontinued operations of Beyond6, and CIG are included in the Company's Other Segment. Summarized operating results of the discontinued operations are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ — $ — $ — $ 1.7 Life, accident and health earned premiums, net — — — 55.7 Net investment income — — — 92.4 Realized/unrealized gains on investments — — — 5.1 Total revenue — — — 154.9 Cost of revenue — — — 0.8 Policy benefits, changes in reserves, and commissions — — — 126.0 Selling, general and administrative — — — 21.1 Depreciation and amortization — — — (11.0) Income from operations — — — 18.0 Interest expense — — — (0.5) Loss on sale and liquidation of subsidiaries — (200.3) — (159.9) Other loss — — — (3.1) Pre-tax loss from discontinued operations — (200.3) — (145.5) Income tax expense — — — (4.4) Loss from discontinued operations $ — $ (200.3) $ — $ (149.9) Assets Held for Sale As of September 30, 2022 the Company had no assets held for sale, and as of December 31, 2021, the Company had approximately $1.5 million of other current assets related to discontinued operations which were classified in Assets held for sale in the Condensed Consolidated Balance Sheet.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	11. Leases Operating lease right-of-use-assets and assets held under finance leases are recognized in the Condensed Consolidated Balance Sheets within Other assets and Property, plant and equipment, net, respectively. Operating lease liabilities and finance lease liabilities are recognized in the Condensed Consolidated Balance Sheets within Other liabilities and Debt obligations, respectively. As of September 30, 2022 and December 31, 2021, lease right-of-use assets and lease liabilities consist of the following (in millions): September 30, December 31, Right-of-use assets: Operating lease (Other assets) $ 65.7 $ 69.6 Finance lease (Property, plant and equipment, net) 2.2 0.2 Total right-of-use assets $ 67.9 $ 69.8 Lease liabilities: Current portion of operating lease (Other current liabilities) $ 17.3 $ 15.5 Non-current portion of operating lease (Other liabilities) 53.2 58.5 Finance lease (Debt obligations) 2.2 0.1 Total lease liabilities $ 72.7 $ 74.1 The tables below present financial information associated with the Company's leases. The Company has entered into operating and finance lease agreements primarily for land, office space, equipment and vehicles, expiring between 2022 and 2045. The following table summarizes the components of lease expense (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.2 $ 0.2 $ 0.8 Interest on lease liabilities — — — — Net finance lease cost 0.1 0.2 0.2 0.8 Operating lease cost 5.8 7.9 17.6 15.7 Variable lease cost 0.1 0.1 0.4 0.3 Sublease income (0.1) — (0.5) — Total lease cost $ 5.9 $ 8.2 $ 17.7 $ 16.8 Cash flow information related to leases is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases $ — $ 0.1 $ 0.1 $ 0.6 Operating cash flows from operating leases $ 5.6 $ 8.1 $ 17.6 $ 16.0 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1.7 $ — $ 2.2 $ — Operating leases $ 2.8 $ 1.7 $ 10.5 $ 42.9 The weighted-average remaining lease term and the weighted-average discount rate for finance leases and operating leases for the periods presented are as follows: September 30, December 31, Weighted-average remaining lease term (years) - operating lease 7.5 7.5 Weighted-average remaining lease term (years) - finance lease 1.6 2.3 Weighted-average discount rate - operating lease 5.4 % 5.4 % Weighted-average discount rate - finance lease 5.6 % 4.2 % As of September 30, 2022, undiscounted cash flows for finance and operating leases are as follows (in millions): Operating Finance 2022 $ 5.1 $ 0.1 2023 19.2 1.8 2024 13.4 0.3 2025 10.0 0.1 2026 6.8 — Thereafter 31.6 — Total future lease payments 86.1 2.3 Less: Present values (15.6) (0.1) Total lease liability balance $ 70.5 $ 2.2 In November 2021, INNOVATE Corp. entered into a ten-year lease agreement for a special purpose space in Palm Beach, Florida. The new lease has not yet commenced, but will require future monthly lease payments of approximately $0.2 million over the entire lease term and yearly common area maintenance charges of $0.6 million, both of which are subject to 3% annual upward adjustments, with total square footage of 20,950. The new lease also provides for the Company to receive an allowance from the landlord of $2.1 million to be used toward costs to design, engineer, install, supply and construct improvements, payable at the end of the construction period. The future lease payments and unexpended amounts under the allowance are not yet recorded on our consolidated balance sheet. We expect the accounting lease commencement date for this initial portion of the lease for financial reporting purposes to begin in 2024.
Leases	11. Leases Operating lease right-of-use-assets and assets held under finance leases are recognized in the Condensed Consolidated Balance Sheets within Other assets and Property, plant and equipment, net, respectively. Operating lease liabilities and finance lease liabilities are recognized in the Condensed Consolidated Balance Sheets within Other liabilities and Debt obligations, respectively. As of September 30, 2022 and December 31, 2021, lease right-of-use assets and lease liabilities consist of the following (in millions): September 30, December 31, Right-of-use assets: Operating lease (Other assets) $ 65.7 $ 69.6 Finance lease (Property, plant and equipment, net) 2.2 0.2 Total right-of-use assets $ 67.9 $ 69.8 Lease liabilities: Current portion of operating lease (Other current liabilities) $ 17.3 $ 15.5 Non-current portion of operating lease (Other liabilities) 53.2 58.5 Finance lease (Debt obligations) 2.2 0.1 Total lease liabilities $ 72.7 $ 74.1 The tables below present financial information associated with the Company's leases. The Company has entered into operating and finance lease agreements primarily for land, office space, equipment and vehicles, expiring between 2022 and 2045. The following table summarizes the components of lease expense (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.2 $ 0.2 $ 0.8 Interest on lease liabilities — — — — Net finance lease cost 0.1 0.2 0.2 0.8 Operating lease cost 5.8 7.9 17.6 15.7 Variable lease cost 0.1 0.1 0.4 0.3 Sublease income (0.1) — (0.5) — Total lease cost $ 5.9 $ 8.2 $ 17.7 $ 16.8 Cash flow information related to leases is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases $ — $ 0.1 $ 0.1 $ 0.6 Operating cash flows from operating leases $ 5.6 $ 8.1 $ 17.6 $ 16.0 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1.7 $ — $ 2.2 $ — Operating leases $ 2.8 $ 1.7 $ 10.5 $ 42.9 The weighted-average remaining lease term and the weighted-average discount rate for finance leases and operating leases for the periods presented are as follows: September 30, December 31, Weighted-average remaining lease term (years) - operating lease 7.5 7.5 Weighted-average remaining lease term (years) - finance lease 1.6 2.3 Weighted-average discount rate - operating lease 5.4 % 5.4 % Weighted-average discount rate - finance lease 5.6 % 4.2 % As of September 30, 2022, undiscounted cash flows for finance and operating leases are as follows (in millions): Operating Finance 2022 $ 5.1 $ 0.1 2023 19.2 1.8 2024 13.4 0.3 2025 10.0 0.1 2026 6.8 — Thereafter 31.6 — Total future lease payments 86.1 2.3 Less: Present values (15.6) (0.1) Total lease liability balance $ 70.5 $ 2.2 In November 2021, INNOVATE Corp. entered into a ten-year lease agreement for a special purpose space in Palm Beach, Florida. The new lease has not yet commenced, but will require future monthly lease payments of approximately $0.2 million over the entire lease term and yearly common area maintenance charges of $0.6 million, both of which are subject to 3% annual upward adjustments, with total square footage of 20,950. The new lease also provides for the Company to receive an allowance from the landlord of $2.1 million to be used toward costs to design, engineer, install, supply and construct improvements, payable at the end of the construction period. The future lease payments and unexpended amounts under the allowance are not yet recorded on our consolidated balance sheet. We expect the accounting lease commencement date for this initial portion of the lease for financial reporting purposes to begin in 2024.

Other Assets

Other Assets	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	12. Other Assets Other assets, which are reflected in non-current assets in the Condensed Consolidated Balance Sheets, consist of the following (in millions): September 30, December 31, Right-of-use assets $ 65.7 $ 69.6 Restricted cash - non-current 1.5 — Other 4.2 3.7 Total other assets $ 71.4 $ 73.3 For the nine months ended September 30, 2022, the Company recorded impairment charges to right-of-use assets of $0.4 million, which are reflected in Other operating (income) loss, related to FCC licenses impaired. Refer to Note 8. Goodwill and Intangibles, Net for additional information.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	13. Accrued Liabilities Accrued liabilities consist of the following (in millions): September 30, December 31, Accrued expenses and other current liabilities $ 21.7 $ 24.5 Accrued payroll and employee benefits 40.4 38.9 Accrued interest 25.8 29.6 Accrued income taxes 0.3 0.4 Total accrued liabilities $ 88.2 $ 93.4

Debt Obligations

Debt Obligations	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt Obligations	14. Debt Obligations Debt obligations consist of the following (in millions): September 30, December 31, Infrastructure 3.25% Note due 2026 $ 101.0 $ 107.2 PRIME minus 0.85% Line of Credit due 2024 107.7 30.4 4.00% Note due 2024 17.5 25.0 8.00% Note due 2024 19.1 19.6 11.00% Note due 2024 — 6.3 Obligations under finance leases 2.2 0.1 Spectrum 8.50% Note due 2022 19.3 19.3 10.50% Note due 2022 32.9 32.9 Life Sciences 12.00% Note due 2022 10.0 — Non-Operating Corporate 8.50% Senior Secured Notes, due 2026 330.0 330.0 7.50% Convertible Senior Notes, due 2026 51.8 51.8 7.50% Convertible Senior Notes, due 2022 — 3.2 LIBOR plus 5.75% Line of Credit due 2024 20.0 5.0 711.5 630.8 Unamortized issuance discount, issuance premium, and deferred financing costs (2.2) (4.5) Less: current portion of debt obligations (81.4) (69.5) Debt obligations $ 627.9 $ 556.8 Aggregate finance lease and debt payments, including interest, are as follows (in millions): Finance Leases Debt Total 2022 $ 0.1 $ 79.2 $ 79.3 2023 1.8 62.3 64.1 2024 0.3 194.2 194.5 2025 0.1 41.2 41.3 2026 — 469.8 469.8 Thereafter — — — Total minimum principal and interest payments 2.3 846.7 849.0 Less: Amount representing interest (0.1) (137.4) (137.5) Total aggregate finance lease and debt payments $ 2.2 $ 709.3 $ 711.5 The interest rates on the finance leases range from approximately 2.0% to 6.0%. Infrastructure In May 2021, DBMG repaid its LIBOR plus 1.50% revolving line of credit (the "Revolving Line") under the Credit and Security Agreement with Wells Fargo Bank and its term loan due 2023 (the "TCW Loan") under a financing agreement with TCW Asset Management Company LLC. In addition, DBMG entered into a new credit facility with UMB Bank ("UMB"). Under the terms of the agreement, UMB agreed to a $110.0 million term loan ("UMB Term Loan") and $110.0 million revolving credit agreement ("UMB Revolving Line"). The UMB Term loan expires in 2026 and will bear interest at a rate of 3.25% with an effective interest rate of 3.25%. The UMB Revolving Line expires in 2024 and bears interest at a rate of Prime Rate minus 0.85%. The proceeds were used to fully repay DBMG's existing debt obligations, fund a portion of the Banker Steel acquisition, and provide additional working capital capacity to DBMG. The 2021 extinguishment of the Revolving Line and the TCW Loan yielded a loss on extinguishment of $1.6 million included in Loss on early extinguishment or restructuring of debt in the Condensed Consolidated Statement of Operations. The UMB Revolving Line associated with our Infrastructure segment contains customary restrictive and financial covenants related to debt levels and performance, including a Fixed Coverage Ratio covenant, as defined in the agreement. On August 2, 2022, DBMG negotiated and finalized an amendment to its UMB Revolving Line which included a retrospective change to the terms of the Fixed Coverage Ratio, and an increase in the UMB Revolving Line commitment from $110.0 million to $135.0 million, among other things. Spectrum On October 24, 2019, Spectrum issued $78.7 million 364-day secured notes (the "2020 Notes"). The 2020 Notes were comprised of a $36.2 million, 8.50% tranche funded by an affiliate of MSD Partners, L.P. (the “8.50% Note”). The remaining $42.5 million, 10.50% tranche (the “10.50% Note”) was a modification of the existing Secured Note, with certain institutional investors. The 2020 Notes had an original maturity date of October 2020, and were amended multiple times during 2020 as further described below. The net proceeds from the financing were used to retire Broadcasting’s existing debt, as well as fund acquisitions, working capital and general corporate purposes. In connection with the issuance of the 10.50% Note due 2020, Spectrum issued warrants to the same institutional investors to purchase 50,000 shares of common stock at $176.4 per share for a total purchase price of $8.8 million, or net settled, if exercised as of the issuance date, and as may be adjusted at any future exercise of the warrant pursuant to its terms. The warrant has a five-year term and is immediately exercisable. In February 2020, Spectrum amended its agreement governing its 8.50% Note funded by MSD Partners, L.P., increasing the principal balance to $39.3 million. The proceeds were used to repay principal and interest on existing debt. In August 2020, Spectrum modified its agreement with MSD Partners, L.P. and Great American Life Insurance Company to extend the maturity on its 8.50% Note and 10.50% Note to October 2021. In September 2020, Spectrum further amended its agreement governing its 8.50% Note, increasing the principal balance by $4.0 million to $43.3 million. The proceeds were used to repay principal and interest on existing debt and for general business purposes. In November 2020, Spectrum paid down $2.9 million of its 8.50% Note and $3.0 million on other various notes. In December 2020, Spectrum paid down $21.0 million and $9.6 million of its 8.50% Note and 10.50% Note, respectively from the proceeds from the sale of stations. On August 30, 2021, Broadcasting repurchased $1.0 million of DTV's outstanding notes payable, inclusive of accrued interest, to certain institutional investors. Also on August 30, 2021, DTV extended its remaining outstanding notes by 60 days. On October 21, 2021, Broadcasting entered into the Fifth Omnibus Amendment to Secured Notes, Consent and Second Amendment to Asset Sale Under Secured Notes and Intercreditor Agreement (the “Amendment”), which, among other things, extended $52.2 million of its Senior Secured Notes, due October 21, 2021, through November 30, 2022. Concurrently, Broadcasting completed the last of a series of repurchases of all the outstanding secured notes, inclusive of accrued interest, of DTV America Corporation (“DTV”) for a total consideration of $6.2 million using a combination of cash on hand and proceeds from the sales on non-core assets. On October 26, 2021, Broadcasting repurchased the outstanding convertible promissory notes of DTV for a total consideration of $0.7 million using proceeds from the sales of non-core assets. Subsequent to these acquisitions, DTV’s debt is held by Broadcasting and eliminated in consolidation. Life Sciences On June 27, 2022, R2 Technologies issued a $0.5 million short-term 90-day 12.0% bridge financing loan with Lancer Capital, LLC, a related party, an entity controlled by Avram A. Glazer, the Chairman of the Board of Directors. On July 13, 2022, R2 Technologies entered into a note purchase agreement with Lancer Capital, LLC. The note payable bears interest at 12.0% per annum and was funded in two tranches. The first tranche of $5.0 million closed on July 13, 2022, and included the settlement of a $0.5 million short-term 90-day 12.0% bridge financing loan made on June 27, 2022 by Lancer Capital, LLC, and an additional $4.5 million in cash. The second tranche of $5.0 million closed on August 8, 2022. The note is payable on the earlier of December 31, 2022 or within five business days from the date on which R2 Technologies receives greater than $10.0 million from an equity or debt financing event. For the three and nine months ended September 30, 2022, R2 Technologies recognized interest expense related to the contractual interest coupon with Lancer Capital, LLC of $0.2 million. Non-Operating Corporate 2026 Senior Secured Notes On February 1, 2021, INNOVATE repaid its 2021 Senior Secured Notes and issued $330.0 million aggregate principal amount of 8.50% senior secured notes due 2026 (the "2026 Senior Secured Notes"). The 2026 Senior Secured Notes were issued under an indenture dated February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association, a national banking association ("U.S. Bank"), as trustee (the "Secured Indenture"). In addition, the Company entered into exchange agreements with certain holders of approximately $51.8 million aggregate principal amount of its existing $55.0 million 7.50% convertible senior notes due 2022 (the "2022 Convertible Notes"), pursuant to which the Company exchanged such holders' 2022 Convertible Notes for newly issued 7.50% convertible notes due 2026 (the "2026 Convertible Notes"). The 2026 Senior Secured Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company accounted for the transactions under the debt extinguishment model as the present value of cash flows under the terms of the 2026 Senior Secured Notes and 2026 Convertible Notes was at least 10% different from the present value of the remaining cash flows under the 2021 Senior Secured Notes and the 2022 Convertible Notes. The extinguishment of the 2021 Senior Secured Notes yielded a loss on extinguishment of $4.5 million. The extinguishment of the $51.8 million of 2022 Convertible Notes yielded a loss on extinguishment of $5.5 million, an acceleration of the amortization of discount of $5.3 million, and extinguishment of the bifurcated conversion option classified as equity of $7.7 million. The 2026 Senior Secured Notes were issued at 100% of par, with a stated interest rate of 8.50% and an effective interest rate of 9.26%, which reflects $2.7 million of deferred financing fees. For the nine months ended September 30, 2022 and 2021, interest expense recognized for the period relating to both the contractual interest coupon and amortization of the deferred financing fees was $22.6 million and $19.7 million, respectively. 2026 Convertible Notes As of September 30, 2022, the 2026 Convertible Notes had a net carrying value of $59.8 million and an unamortized premium of $8.8 million. Based on the closing price of our common stock of $0.70 on September 30, 2022, the if-converted value of the 2026 Convertible Notes did not exceed its principal value. For the nine months ended September 30, 2022 and 2021, interest expense recognized for the period relating to both the contractual interest coupon and amortization of discount net of premium was $1.5 million and $1.3 million, respectively. 2022 Convertible Notes On June 1, 2022, the 2022 Convertible Notes of $3.2 million matured, and the Company repaid the principal and accrued interest upon maturity. For the nine months ended September 30, 2022 and 2021, interest expense recognized for the period relating to both the contractual interest coupon and amortization of the discount on the 2022 Convertible Notes was $0.2 million and $0.3 million, respectively. Line of Credit On February 23, 2021, the Company entered into a third amendment (the "Amendment") of the 6.75% line of credit with MSD PCOF Partners IX, LLC ("Revolving Credit Agreement"). Among other things, the Amendment (i) increases the aggregate principal amount of the Revolving Credit Agreement to $20.0 million, (ii) extends the maturity date of the Revolving Credit Amendment to February 23, 2024, (iii) updates the affirmative and negative covenants contained in the Amended Credit Agreement so that they are substantially consistent with the affirmative and negative covenants contained in the indenture that governs the 2026 Senior Secured Notes and (iv) reduces the interest rate margin applicable to loans borrowed under the Amended Credit Agreement to 5.75% from the 6.75% described above. Except as modified by the Amendment, the terms of the Revolving Credit Agreement remain in effect. In May 2021, INNOVATE drew $5.0 million under the Revolving Credit Agreement. In July 2022, the Company drew an additional $15.0 million under the Revolving Credit Agreement.

Other Liabilities

Other Liabilities	9 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	15. Other Liabilities Other liabilities, which are reflected in non-current liabilities in the Condensed Consolidated Balance Sheets, consist of the following (in millions): September 30, December 31, Lease liability, net of current portion $ 53.2 $ 58.5 Other 4.4 4.8 Total other liabilities $ 57.6 $ 63.3

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The Company used the Annual Effective Tax Rate ("ETR") approach of ASC 740-270, Interim Reporting, to calculate its 2022 interim tax provision. Income tax benefit was $2.0 million and an expense of $0.1 million for the three months ended September 30, 2022 and 2021, respectively. The income tax benefit recorded for the three months ended September 30, 2022 relates to the net tax savings of $2.9 million from the CGIC consolidation in the 2021 tax return, resulting in a partial release of the valuation allowance. See Note 10. Dispositions, Deconsolidations and Discontinued Operations for information regarding the transaction. This was partially offset by income tax expense as calculated under ASC 740 for taxpaying entities. Additionally, the tax benefits associated with losses generated by the INNOVATE Corp. U.S. consolidated income tax return and certain other businesses have been reduced by a full valuation allowance as we do not believe it is more-likely-than-not that the losses will be utilized. The income tax expense recorded for the three months ended September 30, 2021 primarily related to the projected expense as calculated under ASC 740 for taxpaying entities. Additionally, the tax benefits associated with losses generated by the INNOVATE Corp. U.S. consolidated income tax return and certain other businesses have been reduced by a full valuation allowance as we do not believe it is more-likely-than-not that the losses will be utilized. Income tax expense was $1.6 million and $3.8 million for the nine months ended September 30, 2022 and 2021, respectively. The income tax expense recorded for the nine months ended September 30, 2022 primarily relates to the projected expense as calculated under ASC 740 for taxpaying entities. Additionally, the tax benefits associated with losses generated by the INNOVATE Corp. U.S. consolidated income tax return and certain other businesses have been reduced by a full valuation allowance as we do not believe it is more-likely-than-not that the losses will be utilized. This was partially offset by the net tax savings of $2.9 million from the CGIC consolidation in the 2021 tax return, resulting in a partial release of the valuation allowance. The income tax expense recorded for the nine months ended September 30, 2021 primarily relates to the projected expense as calculated under ASC 740 for taxpaying entities. Additionally, the tax benefits associated with losses generated by the INNOVATE Corp. U.S. consolidated income tax return and certain other businesses have been reduced by a full valuation allowance as we do not believe it is more-likely-than-not that the losses will be utilized. Net Operating Losses At December 31, 2021, the Company had gross U.S. net operating loss carryforwards available to reduce future taxable income in the amount of $239.6 million, of which a portion is subject to annual limitation under IRC Sec. 382. This includes $75.1 million of additional U.S. net operating loss carryforwards resulting from the CGIC consolidation in the 2021 tax return. See Note 10. Dispositions, Deconsolidations and Discontinued Operations for information regarding the transaction. Based on estimates as of September 30, 2022, the Company expects that approximately $170.9 million of the gross U.S. net operating loss carryforwards would be available to offset taxable income in 2022. This estimate may change based on changes to actual results reported on the 2021 U.S. tax return. The amount of U.S. net operating loss carryforwards reflected in the financial statements differs from the amounts reported on the U.S. tax return due to uncertain tax positions related to tax laws and regulations that are subject to varied interpretation by the IRS. Additionally, as of December 31, 2021, the Company had $103.9 million of gross U.S. net operating loss carryforwards from its subsidiaries that do not qualify to be included in the INNOVATE Corp. U.S. consolidated income tax return, including $66.1 million from R2, $33.5 million from DTV America, and other entities of $4.3 million. Unrecognized Tax Benefits The Company follows the provision of ASC 740-10, Income Taxes, which prescribes a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return. The Company is subject to challenge from various taxing authorities relative to certain tax planning strategies, including certain intercompany transactions as well as regulatory taxes. The Company did not have any unrecognized tax benefits as of December 31, 2021 related to uncertain tax positions that would impact the effective income tax rate if recognized. The Company has reduced the net operating loss carryforward by $58.7 million for uncertain tax positions based on our interpretation of tax laws and regulations that are subject to varied interpretation by the IRS. Examinations The Company conducts business globally, and as a result, the Company or one or more of its subsidiaries files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. In the normal course of business the Company is subject to examination by taxing authorities throughout the world. The open tax years contain matters that could be subject to differing interpretations of applicable tax laws and regulations as they relate to the amount, character, timing or inclusion of revenue and expenses or the applicability of income tax credits for the relevant tax period. Given the nature of tax audits there is a risk that disputes may arise. Tax years 2002 - 2020 remain open for examination.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies Litigation The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s Condensed Consolidated Financial Statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its Condensed Consolidated Financial Statements. The Company records a liability in its Condensed Consolidated Financial Statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its Condensed Consolidated Financial Statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's Condensed Consolidated Financial Statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. Based on a review of the current facts and circumstances with counsel in each of the matters disclosed, management has provided for what is believed to be a reasonable estimate of loss exposure. While acknowledging the uncertainties of litigation, management believes that the ultimate outcome of litigation will not have a material effect on its financial position and will defend itself vigorously. VAT assessment On February 20, 2017, and on August 15, 2017, the Company's subsidiary, PTGi International Carrier Services Ltd. (“PTGi-ICS Ltd”), received notices from Her Majesty’s Revenue and Customs office in the U.K. ("HMRC") indicating that it was required to pay certain Value-Added Taxes ("VAT") for the 2015 and 2016 tax years. On February 15, 2022, the Upper Tribunal (Tax and Chancery) Chamber (the "Tax Tribunal") found in favor of PTGi-ICS Ltd. HMRC has acknowledged that it will not appeal the Tax Tribunal’s decision and it must pay reasonable legal fees incurred by PTGi-ICS Ltd. On August 1, 2022 ICS received £1.1 million ($1.3 million) from HMRC for the VAT refunds previously withheld. ICS is waiting on the repayment of the outstanding interest and costs. The Company is working with HMRC agents to obtain full resolution. Fair Value Investments Litigation On October 1, 2020, Fair Value Investments Incorporated (“FVI”) filed a putative stockholder class action and derivative complaint in the Delaware Court of Chancery (the "Court") against INNOVATE Corp. and certain of DBMG’s current and former officers and directors, including current and former INNOVATE officers and directors AJ Stahl, Kenneth S. Courtis, Robert V. Leffler, Jr., Philip A. Falcone, Michael J. Sena, and Paul Voigt (together with INNOVATE, the “INNOVATE Defendants”) styled Fair Value Investments Incorporated v. Roach, et al., C.A. No. 2020-0847-JTL (Del. Ch.) (the “FVI Action”). In the FVI Action, FVI alleges that the Company, in its capacity as DBMG’s controlling stockholder, and DBMG’s current and former officers and directors breached their fiduciary duties to DBMG and DBMG’s minority stockholders by approving certain transactions that allegedly provide disproportionate benefits to the Company. FVI challenges the following transactions: (i) DBMG’s payments to the Company from 2016–present pursuant to a Tax Sharing Agreement between DBMG and the Company; (ii) DBMG acting as a guarantor or providing collateral for loans taken on by the Company; (iii) DBMG’s issuance of dividends to its common and preferred stockholders in 2017–2020; (iv) DBMG’s issuance of preferred stock to the Company to finance DBMG’s 2018 acquisition of GrayWolf Industrial; and (v) the Company’s appointment of directors to DBMG’s board of directors by written consent in lieu of holding an annual stockholder meeting. On February 23, 2021, FVI filed an Amended Verified Stockholder Class Action Complaint (the "Amended Complaint"). In the Amended Complaint, FVI named two additional defendants: the Company’s Chief Executive Officer, Wayne Barr, and DBMG’s General Counsel, Scott D. Sherman. The Amended Complaint includes additional fact allegations in support of the largely similar claims raised in the original complaint. Defendants moved to dismiss the Amended Complaint on April 23, 2021. The Court heard argument on the motions to dismiss on January 21, 2022. Ruling from the bench, the Court granted Defendants’ motions to dismiss, in part. The Court dismissed all claims against all individual defendants other than Ronald Yagoda, including all claims against Messrs. Barr, Stahl, Courtis, Leffler, Falcone, Sena, and Voigt. As to the two remaining defendants - INNOVATE Corp. and Yagoda - the Court dismissed all claims regarding: (i) DBMG acting as a guarantor or providing collateral for loans by the Company; (ii) DBMG’s issuance of dividends to its common and preferred stockholders in 2017–2020; (iii) the Company’s appointment of directors to DBMG’s board of directors by written consent in lieu of holding an annual stockholder meeting; and (iv) DBMG’s payments to the Company in 2016 and May 2017 pursuant to a Tax Sharing Agreement between DBMG and the Company. The Company believes the surviving claims in the FVI Amended Complaint relating to (i) DBMG’s payments to the Company after May 2017 pursuant to a Tax Sharing Agreement between DBMG and the Company and (ii) DBMG’s issuance of preferred stock to the Company to finance DBMG’s 2018 acquisition of GrayWolf Industrial are without merit. Discovery on the two remaining claims is underway and, if necessary, trial in this action is expected to occur in the second half of 2023. The Company intends to vigorously defend this litigation. DTV Derivative Litigation On March 15, 2021, twenty-two DTV stockholders and eight holders of DTV stock options filed a stockholder class action and derivative complaint in the Delaware Court of Chancery in an action styled Bocock, et al., v. HC2 Holdings, Inc. et al., C.A. No. 2021-0224 (Del. Ch.). Plaintiffs named as defendants INNOVATE Corp. (f/k/a HC2 Holdings, Inc.), HC2 Broadcasting Holdings, Inc., HC2 Broadcasting Inc., and Continental General Insurance Corporation (the “INNOVATE Entities”) and certain current and former officers and directors of the INNOVATE Entities and DTV, including Philip Falcone, Michael Sena, Wayne Barr, Jr., Les Levi, Paul Voigt, Ivan Minkov, and Paul Robinson (the “Individual Defendants”). Plaintiffs principally allege that the defendants breached their fiduciary duties and/or aided and abetted breaches of fiduciary duty by participating in a “scheme” in which the INNOVATE Entities (i) acquired majority voting and operating control over DTV; (ii) exploited that control to misappropriate DTV’s assets and business opportunities for the benefit of the INNOVATE Entities; and (iii) purchased DTV stock at a discount to fair value and diminished the value of DTV stock options. Plaintiffs allege that the Individual Defendants (i) “prompted” the INNOVATE Entities to purchase more than 100 low-power television (“LPTV”) broadcast stations originally identified for potential acquisition by DTV, (ii) allowed the INNOVATE Entities to misappropriate DTV technology, known as “DTV Cast,” (iii) caused DTV to transfer unspecified LPTV broadcasting station licenses to INNOVATE affiliates “without paying any value,” and (iv) transferred to the INNOVATE Entities unspecified DTV broadcasting stations that had been “repacked” by the FCC. Defendants moved to dismiss the Complaint on May 19, 2021. On June 23, 2021, plaintiffs amended their complaint. In the amended complaint, plaintiffs assert the same claims they asserted in their initial complaint, added a claim for waste associated with DTV’s purported transfer of licenses and construction permits for less than fair value, and dropped Paul Robinson as a defendant. Defendants moved to dismiss the amended complaint in its entirety on August 25, 2021, and the parties completed briefing on the motions to dismiss on November 10, 2021. The Court heard argument on the motions to dismiss on March 29, 2022. On June 28, 2022, the Court requested that the parties submit supplemental briefing on the motions to dismiss by July 20, 2022. The parties completed the supplemental briefing on July 20, 2022. On October 28, 2022, the Court issued a Memorandum Opinion on Defendants’ motion to dismiss the Complaint. First, the Court dismissed all claims against Continental General Insurance Corporation for lack of personal jurisdiction. Second, the Court dismissed all claims the stockholder plaintiffs purported to assert directly. Third, the Court dismissed as time-barred all claims challenging conduct that occurred before March 15, 2018, including claims challenging (i) the November 2017 acquisition of Azteca America by INNOVATE; (ii) INNOVATE’s purported usurpation of the so-called “DTV Cast” technology; and (iii) the WFWC-CD Station acquisition. Fourth, the Court dismissed claims associated with the INNOVATE Entities’ purported purchases of unidentified broadcasting stations. Fifth, the Court dismissed all claims challenging the Expense Sharing Agreement, and the Right to Use Agreement between INNOVATE and DTV, and certain Stock-Based Compensation Agreements. Sixth, the Court dismissed the aiding and abetting claim against the INNOVATE Entities. Seventh, the Court dismissed the civil conspiracy claim as to all defendants. Lastly, the Court dismissed the option-holders’ claim for tortious interference with prospective business opportunities. Thus, after the Court issued its October 28, 2022 Memorandum Opinion, the only claims to survive Defendants’ motion to dismiss are (i) a derivative claim against the INNOVATE Entities (other than Continental General), Levi, and Falcone for breach of fiduciary duty in connection with the $0.1 million Frank Digital acquisition; (ii) a derivative claim for breach of fiduciary duty against the INNOVATE Entities (other than Continental General), in their capacities as DTV’s controlling stockholders, relating to the sale of six licenses (for less than $0.5 million) in connection with the Gray Media sale; (iii) a derivative claim for breach of fiduciary duty against the INNOVATE Entities (other than Continental General) and Levi in connection with the transfer of licenses ultimately sold to TV-49 for $0.1 million; and (iv) a derivative claim for waste against Levi and Falcone in connection with the sale of two stations to Lowcountry, which Lowcountry later sold for $0.2 million and $0.4 million, respectively. The Company believes these remaining claims are without merit, and the Company intends to vigorously defend this litigation. Insurance Company Books and Records Demand On July 28, 2021, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the Company’s sale of its Insurance segment. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation. INNOVATE Books and Records Demand On June 6, 2022, the Company received a demand from a Company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the Company’s lease agreement for a special purpose space in Palm Beach, Florida; the request by certain Company stockholders for a waiver of the share purchase limitations in the Company’s Tax Benefits Preservation Plan; and the receipt of a letter by the Audit Committee of the Board on May 18, 2022 from Michael Gorzynski, on behalf of MG Capital Management, Ltd. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation. Other Commitments and Contingencies Letters of Credit and Performance Bonds As of September 30, 2022, DBMG had outstanding letters of credit of $2.6 million under credit and security agreements and performance bonds of $1,057.8 million. As of December 31, 2021, DBM had outstanding letters of credit of $13.5 million under credit and security agreements and performance bonds of $900.8 million. DBMG’s contract arrangements with customers sometimes require DBMG to provide performance bonds to partially secure its obligations under its contracts. Bonding requirements typically arise in connection with private contracts and sometimes with respect to certain public work projects. DBMG’s performance bonds are obtained through surety companies and typically cover the entire project price. HMN Equity Interest On October 30, 2019, the Company announced the sale of its New Saxon 2019 Limited (“New Saxon”) stake in HMN, its 49% joint venture with Huawei Technologies Co., Ltd., to Hengtong Optic-Electric Co Ltd ("Hengtong"). Under the terms of the agreement, the sale of New Saxon’s 49% interest in HMN will be affected in two tranches. The first tranche, the sale of the portion of New Saxon’s 30% interest of HMN, closed on May 12, 2020 (the "First HMN Close"). The remaining 19% interest of HMN is retained by New Saxon and subject to a put option agreement by New Saxon, exercisable starting on the second year anniversary of the closing date of the First HMN Close at a price equal to the greater of the share price paid for the 30% interest or fair market value as of the exercisable date. On June 24, 2022, New Saxon entered into a supplemental agreement for the outright sale of its remaining 19% interest in HMN, which also changed the buyers from a Hong Kong entity to three Chinese entities. There is no guarantee that the transaction will be consummated in the anticipated timeframe, on the contemplated terms or at all. The new agreement preserves the rights under the original put option agreement and the Company has the ability to exercise the put option after October 31, 2022. The significant terms and structure of the transaction have not otherwise changed, and the transaction still requires cash settlement.

Share-based Compensation

Share-based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	18. Share-based Compensation Total share-based compensation expense recognized by the Company and its subsidiaries under all equity compensation arrangements was $0.4 million for both the three months ended September 30, 2022 and 2021, and was $1.7 million for both the nine months ended September 30, 2022 and 2021. All grants are time based and vest either immediately or over a period established at grant, typically with a requisite service period of two Restricted Stock A summary of INNOVATE’s restricted stock activity is as follows: Shares Weighted Average Grant Date Fair Value Unvested - December 31, 2020 628,433 $ 3.93 Granted 593,458 $ 3.81 Vested (514,543) $ 3.89 Forfeited (151,469) $ 4.13 Unvested - December 31, 2021 555,879 $ 3.79 Granted 599,797 $ 3.57 Vested (292,091) $ 3.81 Forfeited (45,289) $ 3.68 Unvested - September 30, 2022 818,296 $ 3.63 The aggregate fair value of the restricted stock awards which vested during the nine months ended September 30, 2022 was $0.8 million. As of September 30, 2022, the total unrecognized stock-based compensation expense related to unvested restricted stock was $2.2 million. The unrecognized compensation cost is expected to be recognized over the remaining weighted average period of 2.2 years. Stock Options A summary of INNOVATE’s stock option activity is as follows: Shares Weighted Average Exercise Price Outstanding - December 31, 2020 4,739,858 $ 5.13 Expired (23,999) $ 5.31 Outstanding - December 31, 2021 4,715,859 $ 5.13 Granted 280,791 $ 3.25 Exercised — — Forfeited — — Expired (1,500) $ 4.06 Outstanding - September 30, 2022 4,995,150 $ 5.02 Eligible for exercise 4,995,150 $ 5.02

Temporary Equity

Temporary Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Temporary Equity	19. Temporary Equity Preferred Shares The Company’s preferred shares authorized, issued and outstanding consisted of the following: September 30, December 31, Preferred shares authorized, $0.001 par value 20,000,000 20,000,000 Series A-3 shares issued and outstanding 6,125 6,125 Series A-4 shares issued and outstanding 10,000 10,000 Preferred Share Activity Series A-3 and A-4 Share Issuance and Conversion On July 1, 2021 (the "Exchange Date") as a part of the sale of CIG, INNOVATE entered into an exchange agreement (the "Exchange Agreement") with the now deconsolidated CGIC, who held the remaining shares of the Series A and Series A-2 Preferred Stock and was eliminated in consolidation prior to the sale of the Insurance segment on July 1, 2021. Per the Exchange Agreement, INNOVATE exchanged 6,125 shares of the Series A and 10,000 shares of the Series A-2 shares that CGIC held for an equivalent number of Series A-3 Convertible Participating Preferred Stock ("Series A-3") and Series A-4 Convertible Participating Preferred Stock ("Series A-4"), respectively. The terms remained substantially the same, except that the Series A-3 and Series A-4 will mature on July 1, 2026. A cash payment of $0.3 million was made as a part of the exchange for accrued and unpaid dividends on the Series A and Series A-2 being exchanged. Upon issuance of the Series A-3 and Series A-4 Preferred Stock on July 1, 2021, the Series A-3 and Series A-4 have been classified as temporary equity in the Company's Consolidated Balance Sheet with a combined redemption value of $16.1 million with a current fair value as of September 30, 2022 of $17.9 million. Dividends. The Series A-3 and Series A-4 Preferred Stock accrue a cumulative quarterly cash dividend at an annualized rate of 7.50%. The accrued values of the Series A-3 and Series A-4 Preferred Stock accrete quarterly at an annualized rate of 4.00% that is reduced to 2.00% or 0.0% if the Company achieves specified rates of growth measured by increases in its net asset value; provided, that the accreting dividend rate will be 7.25% in the event that (A) the daily volume weighted average price ("VWAP") of the Company's common stock is less than a certain threshold amount, (B) the Company's common stock is not registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, (C) the Company's common stock is not listed on certain national securities exchanges or the Company is delinquent in the payment of any cash dividends. The Series A-3 and Series A-4 Preferred Stock is also entitled to participate in cash and in-kind distributions to holders of shares of Company's common stock on an as-converted basis. Subsequent Measurement. The Company has elected to account for the Series A-3 and Series A-4 Preferred Stock by immediately recognizing changes in the redemption value as they occur. The carrying value of the Series A-3 and Series A-4 Preferred Stock will be adjusted to equal what the redemption amount would be as if the redemption were to occur at the end of the reporting period as if it were also the redemption date for the Series A-3 and Series A-4 Preferred Stock. Any cash dividends paid will directly reduce the carrying value of the Series A-3 and Series A-4 Preferred Stock until the carrying value equals the redemption value. The Company has a history of paying dividends on its preferred stock and expects to continue to pay such dividends each quarter. Optional Conversion. Each share of Series A-3 and Series A-4 may be converted by the holder into shares of the Company's common stock at any time based on the then-applicable Conversion Price. Each share of Series A-3 is initially convertible at a conversion price of $4.25 (as it may be adjusted from time to time, the "Series A-3 Conversion Price"), and each share of Series A-4 is initially convertible at a conversion price of $8.25 (as it may be adjusted from time to time, the "Series A-4 Conversion Price") (“collectively the “Conversion Prices”). The Conversion Prices are subject to adjustment for dividends, certain distributions, stock splits, combinations, reclassifications, reorganizations, mergers, recapitalizations and similar events, as well as in connection with issuances of equity or equity-linked or other comparable securities by the Company at a price per share (or with a conversion or exercise price or effective issue price) that is below the Conversion Prices’ (which adjustment shall be made on a weighted average basis). Actual conversion prices at the time of the exchange were $3.52 for the Series A and $5.33 for the Series A-2. Redemption by the Holder / Automatic Conversion. On July 1, 2026, holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem the Series A-3 and Series A-4 at the accrued value per share plus accrued but unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4). Each share of Series A-3 and Series A-4 that is not so redeemed will be automatically converted into shares of the Company's common stock at the Conversion Price then in effect. Upon a change of control (as defined in each Certificate of Designation) holders of the Series A-3 and Series A-4 shall be entitled to cause the Company to redeem their shares of Series A-3 and Series A-4 at a price per share of Series A-3 and Series A-4 equal to the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4 Preferred Stock), and (ii) the value that would be received if the share of Series A-3 and Series A-4 were converted into shares of the Company's common stock immediately prior to the change of control. Redemption by the Company / "Company Call Option". At any time after the third anniversary of the Original Issue Date, May 29, 2014, the Company may redeem the Series A-3/Series A-4, in whole but not in part, at a price per share generally equal to 150% of the accrued value per share, plus accrued but unpaid dividends (to the extent not included in the accrued value of the Series A-3/Series A-4), subject to the holder's right to convert prior to such redemption. Forced Conversion . The Company may force conversion of the Series A-3 and Series A-4 into shares of the Company's common stock if the common stock's thirty-day VWAP exceeds 150% of the then-applicable Conversion Price and the Common Stock’s daily VWAP exceeds 150% of the then-applicable Conversion Price for at least twenty Liquidation Preference . In the event of any liquidation, dissolution or winding up of the Company (any such event, a “Liquidation Event”), the holders of Series A-3 and Series A-4 will be entitled to receive per share the greater of (i) the accrued value of the Series A-3 and Series A-4, plus any accrued and unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4), and (ii) the value that would be received if the share of Series A-4 and Series A-4 were converted into shares of the Company's common stock immediately prior to such occurrence. The Series A-3 and Series A-4 will rank junior to any existing or future indebtedness but senior to the Company's common stock and any future equity securities other than any future senior or pari passu preferred stock issued in compliance with each Certificate of Designation. The Series A-3 Preferred Stock and the Series A-4 Preferred Stock rank at parity. Voting Rights. Except as required by applicable law, the holders of the shares of the Series A-3 and Series A-4 will be entitled to vote on an as-converted basis with the holders of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock (on an as-converted basis), as applicable, and the holders of the Company’s common stock on all matters submitted to a vote of the holders of the Company's common stock with the holders of Series A-3 Preferred Stock and Series A-4 Preferred Stock on certain matters, and separately as a class on certain limited matters. Consent Rights. For so long as any of the Series A-3 and Series A-4 is outstanding, consent of the holders of shares representing at least 75% of certain of the Series A-3 and Series A-4 then outstanding is required for certain material actions. Participation Rights. Pursuant to the securities purchase agreements entered into with the initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock, subject to meeting certain ownership thresholds, certain purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock are entitled to participate, on a pro-rata basis in accordance with their ownership percentage, determined on an as-converted basis, in issuances of equity and equity linked securities by the Company. In addition, subject to meeting certain ownership thresholds, certain initial purchasers of the Series A-3 Preferred Stock and the Series A-4 Preferred Stock will be entitled to participate in issuances of preferred securities and in debt transactions of the Company. As of September 30, 2022, Series A-3 Preferred Stock and Series A-4 Preferred Stock were convertible into 1,740,700 and 1,875,533 shares, respectively, of INNOVATE's common stock. Preferred Share Dividends During the nine months ended September 30, 2022 and 2021, INNOVATE's Board of Directors (the "Board") declared cash dividends with respect to INNOVATE’s issued and outstanding Preferred Stock, excluding the Series A and Series A-2 Preferred Stock which was owned by CGIC and was eliminated in consolidation prior to the sale of the Insurance segment on July 1, 2021, as presented in the following table (in millions): 2022 Declaration Date March 31, 2022 June 30, 2022 September 30, 2022 Holders of Record Date March 31, 2022 June 30, 2022 September 30, 2022 Payment Date April 15, 2022 July 15, 2022 October 15, 2022 Total Dividend $ 0.3 $ 0.3 $ 0.3 2021 Declaration Date March 31, 2021 May 29, 2021 September 30, 2021 Holders of Record Date March 31, 2021 May 29, 2021 September 30, 2021 Payment Date April 15, 2021 June 4, 2021 October 15, 2021 Total Dividend $ 0.2 $ 0.1 $ 0.3 DBMGi Series A Preferred Stock Issuance On November 30, 2018, CGIC purchased 40,000 shares of DBMGi's Series A Preferred Stock, which was eliminated in consolidation. On July 1, 2021, as a part of the sale of CIG which resulted in the deconsolidation of the entity, INNOVATE was deemed to have issued $40.9 million of DBMGi Series A Preferred Stock to the now deconsolidated CGIC. Upon issuance of the DBMGi Series A Preferred Stock on July 1, 2021, the DBMGi Series A Preferred Stock has been classified as temporary equity in the Company's Balance Sheet. Redemption Option . The DBMGi Preferred Stock is redeemable at any time, in whole or in part, at the option of the Company, or at any time or by the holder prior to July 2026. Dividends. The DBMGi Series A Preferred Stock will accrue a cumulative quarterly cash or payment in kind dividend at a rate of (a) for the first five years following the date of issuance, (i) 9.00% per annum if dividends are paid in kind or (ii) 8.25% per annum if dividends are paid in cash and (b) starting on the fifth anniversary of the date of issuance, a rate per annum equal to (i) LIBOR (as defined in the Certificate of Designation) plus a spread of 5.85% (together, the “LIBOR Rate”) per annum, plus 0.75% if dividends are paid in kind or (ii) the LIBOR Rate per annum in the case of dividends paid in cash. Subsequent to the transition away from LIBOR beginning in 2023, the Certificate of Designation allows for a LIBOR Successor Rate, which allows the Company to reasonably determine an alternate benchmark rate (including any mathematical or other adjustments to the benchmarks (if any) incorporated therein) giving due consideration to any evolving or then existing convention for similar U.S. dollar denominated syndicated credit facilities for such alternative benchmarks. Subsequent Measurement. The DBMGi Series A Preferred Stock will be subsequently measured each reporting period at its maximum redemption value, which is equal to the stated value plus all accrued, accumulated and unpaid dividends as of the end of each reporting period as they are currently redeemable. The Company pays accrued dividends quarterly in cash (with an option to PIK), and the Company does not expect to make any subsequent measurement adjustments recorded to the initial carrying amount. As such no accretion will be recognized until future dividend payments would otherwise reduce the carrying value below its redemption value. In such a case, the Company will adjust the carrying value to its maximum redemption amount. During the nine months ending September 30, 2022 and 2021, DBMGi's Board of Directors declared dividends with respect to DBMGi’s issued and outstanding Preferred Stock, as presented in the following table (in millions): 2022 Declaration Date March 31, 2022 June 30, 2022 September 30, 2022 Holders of Record Date March 31, 2022 June 30, 2022 September 30, 2022 Payment Date April 15, 2022 July 15, 2022 October 15, 2022 Total Dividend* $ 0.9 $ 0.9 $ 0.9 *The dividends paid on April 15, 2022 and October 15, 2022 were paid in cash. The DBMGi Board of Directors elected to pay the second quarter dividend payable July 15, 2022 in shares. 2021 Declaration Date September 30, 2021 Holders of Record Date September 30, 2021 Payment Date October 15, 2021 Total Dividend $ 0.8

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Parties	20. Related Parties Non-Operating Corporate In September 2018, the Company entered into a 75-month lease for office space. As part of the agreement, INNOVATE was able to pay a lower security deposit and lease payments, and received favorable lease terms as consideration for landlord required cross default language in the event of default of the shared space leased by Harbinger Capital Partners, a company controlled by INNOVATE's former CEO and formerly a related party, in the same building. With the adoption of ASC 842, as of January 1, 2019, this lease was recognized as a right-of-use asset and lease liability on the Condensed Consolidated Balance Sheets. Infrastructure Banker Steel, a subsidiary of DBMG, has leased two office spaces from 2940 Fulks St LLC, a related party that is owned by Donald Banker, CEO of Banker Steel and a related party, with monthly lease payments of $10 thousand and a total lease liability of $0.1 million. For the three months ended September 30, 2022 and 2021, DBMG incurred lease expense of $24 thousand and $23 thousand, respectively, and for the nine months ended September 30, 2022 and 2021, DBMG incurred lease expense of $72 thousand and $31 thousand, respectively. Banker Steel has leased one plane from Banker Aviation LLC, a related party that is owned by Donald Banker, a related party, with monthly lease payments of $0.1 million and a total lease liability of $1.6 million. During the first quarter 2022, one of the two plane leases was terminated. For the three months ended September 30, 2022 and 2021, DBMG incurred lease expense of $0.3 million and $0.4 million, respectively, and for the nine months ended September 30, 2022 and 2021, DBMG incurred lease expense of $1.0 million and $0.6 million, respectively. Banker Steel also had a subordinated 11.0% note payable of $6.3 million to Donald Banker, a related party, which was redeemed in full by DBMG on April 4, 2022. For the three months ended September 30, 2022 and 2021, DBMG incurred interest expense of zero and $0.1 million, respectively, and for both the nine months ended September 30, 2022 and 2021, DBMG incurred interest expense of $0.2 million. Refer to Note 14. Debt Obligations for additional information. Life Sciences For the three and nine months ended September 30, 2022, R2 Technologies incurred approximately $0.1 million and $0.3 million, respectively, of stock compensation and royalty expenses that were paid to Blossom Innovations, LLC, an investor and a related party of R2 Technologies.

Operating Segments and Related

Operating Segments and Related Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Operating Segments and Related Information	21. Operating Segments and Related Information The Company currently has one primary reportable geographic segment - United States and primarily all revenue is derived in the United States. The Company has three reportable operating segments, plus our Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. We also have included a Non-operating Corporate segment. All inter-segment revenues are eliminated on consolidation. The Company's revenue concentrations of 10% and greater are as follows: Three Months Ended September 30, Nine Months Ended September 30, Segment 2022 2021 2022 2021 Customer A Infrastructure 25.2% 18.9% 24.2% 12.2% Customer B Infrastructure * 13.0% * * Customer C Infrastructure 10.1% * * * *Less than 10% revenue concentration Summarized financial information with respect to the Company’s operating segments is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue Infrastructure $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 Life Sciences 1.2 1.6 3.0 2.8 Spectrum 9.1 10.2 28.0 31.3 Total revenue $ 423.0 $ 394.8 $ 1,228.0 $ 810.4 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Income (loss) from operations Infrastructure $ 18.5 $ 12.6 $ 42.2 $ 17.0 Life Sciences (5.5) (4.9) (15.7) (14.2) Spectrum (0.6) (1.2) (4.1) (1.0) Other (0.3) (1.0) (0.4) (1.6) Non-operating Corporate (5.5) (4.4) (15.1) (17.7) Total income (loss) from operations $ 6.6 $ 1.1 $ 6.9 $ (17.5) A reconciliation of the Company's consolidated segment operating income (loss) to consolidated loss from continuing operations before income taxes is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Income (loss) from operations $ 6.6 $ 1.1 $ 6.9 $ (17.5) Interest expense (13.3) (12.8) (38.4) (46.6) Loss on early extinguishment or restructuring of debt — (0.1) — (12.5) Loss from equity investees (1.1) (2.9) (2.1) (4.8) Other (expense) income, net (0.9) 0.6 0.5 4.4 Loss from continuing operations before income taxes $ (8.7) $ (14.1) $ (33.1) $ (77.0) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Depreciation and Amortization Infrastructure $ 5.3 $ 7.4 $ 15.9 $ 13.1 Infrastructure recognized within cost of revenue 3.9 3.4 11.2 8.4 Total Infrastructure 9.2 10.8 27.1 21.5 Life Sciences 0.1 — 0.2 0.1 Spectrum 1.4 1.4 4.4 4.3 Non-operating Corporate — 0.1 0.1 0.1 Total depreciation and amortization $ 10.7 $ 12.3 $ 31.8 $ 26.0 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Capital Expenditures (*) Infrastructure $ 6.9 $ 6.1 $ 13.5 $ 11.6 Life Sciences 0.2 — 0.3 0.5 Spectrum 0.4 0.9 2.5 2.9 Total $ 7.5 $ 7.0 $ 16.3 $ 15.0 (*) The above capital expenditures exclude assets acquired under terms of capital lease and vendor financing obligations. September 30, December 31, Investments Infrastructure $ — $ 0.7 Life Sciences 9.0 10.2 Other 48.7 45.1 Total $ 57.7 $ 56.0 September 30, December 31, Equity Method Investments (included in Investments above) Infrastructure $ — $ 0.7 Life Sciences 3.4 4.2 Other 37.4 33.9 Total $ 40.8 $ 38.8 September 30, December 31, Total Assets Infrastructure $ 893.3 $ 786.4 Life Sciences 18.8 22.0 Spectrum 191.0 198.9 Other 50.4 48.0 Non-operating Corporate 11.7 25.3 Total $ 1,165.2 $ 1,080.6

Basic and Diluted Loss Per Comm

Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share	22. Basic and Diluted Loss Per Common Share Earnings per share ("EPS") is calculated using the two-class method, which allocates earnings among common stock and participating securities to calculate EPS when an entity's capital structure includes either two or more classes of common stock or common stock and participating securities. Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities. As such, shares of any unvested restricted stock of the Company are considered participating securities. The dilutive effect of options and their equivalents (including non-vested stock issued under stock-based compensation plans), is computed using the "if-converted method" as this measurement was determined to be more dilutive between the two available methods in each period. The Company had no dilutive common share equivalents during the three and nine months ended September 30, 2022 and 2021 due to results from continuing operations being a loss, net of tax. The following table presents a reconciliation of net loss used in the basic and diluted EPS calculations (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Loss from continuing operations $ (6.7) $ (14.2) $ (34.7) $ (80.8) Loss from continuing operations attributable to noncontrolling interest and redeemable noncontrolling interest 1.3 2.6 4.5 7.0 Loss from continuing operations attributable to INNOVATE Corp. (5.4) (11.6) (30.2) (73.8) Less: Preferred dividends and deemed dividends from conversions 1.2 1.1 3.6 1.7 Loss from continuing operations attributable to INNOVATE common stockholders (6.6) (12.7) (33.8) (75.5) Loss from discontinued operations — (200.3) — (149.9) Loss from discontinued operations attributable to noncontrolling interest and redeemable noncontrolling interest — — — 0.9 Loss from discontinued operations, net of tax and noncontrolling interest — (200.3) — (149.0) Net loss attributable to common stock and participating preferred stockholders $ (6.6) $ (213.0) $ (33.8) $ (224.5) Earnings allocable to common shares: Participating shares at end of period: Weighted-average common stock outstanding 77.6 77.2 77.5 77.0 Unvested restricted stock — — — — Preferred stock (as-converted basis) — — — — Total 77.6 77.2 77.5 77.0 Percentage of loss allocated to: Common stock 100.0 % 100.0 % 100.0 % 100.0 % Unvested restricted stock — % — % — % — % Preferred stock — % — % — % — % Numerator for loss per share, basic: Net loss from continuing operations attributable to common stock, basic $ (6.6) $ (12.7) $ (33.8) $ (75.5) Net loss from discontinued operations attributable to common stock, basic — (200.3) — (149.0) Net loss attributable to common stock, basic $ (6.6) $ (213.0) $ (33.8) $ (224.5) Earnings allocable to common shares, diluted: Numerator for loss per share, diluted Net loss from continuing operations attributable to common stock, basic $ (6.6) $ (12.7) $ (33.8) $ (75.5) Net loss from discontinued operations attributable to common stock, basic — (200.3) — (149.0) Net loss attributable to common stock, basic $ (6.6) $ (213.0) $ (33.8) $ (224.5) Denominator for basic and dilutive loss per share Weighted average common shares outstanding - basic 77.6 77.2 77.5 77.0 Effect of assumed shares under treasury stock method for stock options and restricted shares and if-converted method for convertible instruments — — — — Weighted average common shares outstanding - diluted 77.6 77.2 77.5 77.0 Loss per share - continuing operations Basic $ (0.09) $ (0.16) $ (0.44) $ (0.98) Diluted $ (0.09) $ (0.16) $ (0.44) $ (0.98) Loss per share - discontinued operations Basic $ — $ (2.59) $ — $ (1.94) Diluted $ — $ (2.59) $ — $ (1.94) Loss per share - Net loss attributable to common stock and participating preferred stockholders Basic $ (0.09) $ (2.75) $ (0.44) $ (2.92) Diluted $ (0.09) $ (2.75) $ (0.44) $ (2.92)

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	23. Fair Value of Financial Instruments Fair Value of Financial Instruments Not Measured at Fair Value The following table presents the carrying amounts and estimated fair values of the Company’s financial instruments, which were not measured at fair value on a recurring basis. The table excludes carrying amounts for cash and cash equivalents and restricted cash, accounts receivable and contract assets, accounts payable, contract liabilities and other current liabilities, and other assets and liabilities that approximate fair value due to relatively short periods to maturity (in millions): September 30, 2022 Fair Value Measurement Using: Carrying Value Estimated Fair Value Level 1 Level 2 Level 3 Assets Other invested assets $ 11.3 $ 11.3 $ — $ — $ 11.3 Total assets not accounted for at fair value $ 11.3 $ 11.3 $ — $ — $ 11.3 Liabilities Debt obligations (1) $ 707.1 $ 637.5 $ — $ 637.5 $ — Total liabilities not accounted for at fair value $ 707.1 $ 637.5 $ — $ 637.5 $ — December 31, 2021 Fair Value Measurement Using: Carrying Value Estimated Fair Value Level 1 Level 2 Level 3 Assets Other invested assets $ 11.3 $ 11.3 $ — $ — $ 11.3 Total assets not accounted for at fair value $ 11.3 $ 11.3 $ — $ — $ 11.3 Liabilities Debt obligations (1) $ 626.3 $ 648.2 $ — $ 648.2 $ — Total liabilities not accounted for at fair value $ 626.3 $ 648.2 $ — $ 648.2 $ — (1) Excludes operating lease obligations accounted for under ASC 842, Leases .

Supplementary Financial Informa

Supplementary Financial Information	9 Months Ended
	Sep. 30, 2022
Offsetting [Abstract]
Supplementary Financial Information	24. Supplementary Financial Information Supplemental Cash Flow Information The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions): September 30, 2022 2021 Cash and cash equivalents, beginning of period $ 45.5 $ 43.8 Restricted cash 2.0 1.5 Restricted cash included in other assets (non-current) — — Total cash, cash equivalents and restricted cash $ 47.5 $ 45.3 Cash and cash equivalents, end of period $ 25.8 $ 55.5 Restricted cash 0.4 8.6 Restricted cash included in other assets (non-current) 1.5 — Total cash and cash equivalents and restricted cash $ 27.7 $ 64.1 Cash and cash equivalents classified in Assets held for sale, beginning of period $ — $ 195.2 Restricted cash classified in Assets held for sale — 0.2 Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ 195.4 Cash and cash equivalents classified in Assets held for sale, end of period $ — $ — Restricted cash classified in Assets held for sale — — Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ — Supplemental cash flow information: Cash paid for interest $ 38.9 $ 31.3 Cash paid for taxes, net of refunds $ 3.8 $ 4.3 Non-cash investing and financing activities: Property, plant and equipment included in accounts payable $ 0.9 $ 2.1 Issuance of preferred stock $ 0.9 $ 19.1 Issuance of redeemable noncontrolling interest $ — $ 40.9 Extinguishment of convertible note in exchange $ — $ 51.8 Issuance of convertible note in exchange $ — $ (51.8) Debt assumed in acquisitions $ — $ 6.3

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	25. Subsequent Events None.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries and all other subsidiaries over which the Company exerts control. All intercompany profits, transactions and balances have been eliminated in consolidation. For the three and nine months ended September 30, 2022, the results of DBMG, Pansend, Genovel, R2, Broadcasting, and GMH have been consolidated into the Company’s results based on guidance from the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" 810, Consolidation) . The remaining interests not owned by the Company are presented as a noncontrolling interest component of total equity.
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). The financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of such information. All such adjustments are of a normal recurring nature. Certain information and note disclosures, including a description of significant accounting policies normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), have been condensed or omitted in these interim financial statements pursuant to such rules and regulations. Certain prior amounts have been reclassified or combined to conform to the current year presentation. These interim financial statements should be read in conjunction with the Company’s annual audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 9, 2022. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results for any subsequent periods or the entire fiscal year ending December 31, 2022.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions used.
Accounting Pronouncements	Accounting Pronouncements Adopted in the Current Year There were no new accounting pronouncements adopted during the nine months ended September 30, 2022. Accounting Pronouncements to be Adopted in 2023 Credit Loss Standard In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) , Measurement of Credit Losses on Financial Instruments

Revenue and Contracts in Proc_2

Revenue and Contracts in Process (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Reconciliation of Revenue from Segments to Consolidated	Revenue from contracts with customers consist of the following (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue Infrastructure $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 Life Sciences 1.2 1.6 3.0 2.8 Spectrum 9.1 10.2 28.0 31.3 Total revenue $ 423.0 $ 394.8 $ 1,228.0 $ 810.4 The following table disaggregates the Life Sciences segment's revenue by type (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Systems and consumables revenue $ 1.2 $ 1.6 $ 3.0 $ 2.8 Total Life Sciences segment revenue $ 1.2 $ 1.6 $ 3.0 $ 2.8
Schedule of Accounts Receivable, net	Accounts receivables, net, from contracts with customers consist of the following (in millions): September 30, December 31, Accounts receivables with customers Infrastructure $ 313.9 $ 226.8 Life Sciences 0.8 0.3 Spectrum 7.1 9.4 Total accounts receivables with customers $ 321.8 $ 236.5 Accounts receivable, net consist of the following (in millions): September 30, December 31, Contracts in progress $ 313.9 $ 226.8 Unbilled retentions 0.4 0.4 Trade receivables 7.8 9.9 Other receivables 6.1 10.6 Allowance for doubtful accounts (0.3) (0.6) Total $ 327.9 $ 247.1
Schedule of Costs and Recognized Earnings in Excess of Billings and Billings in Excess of Costs and Recognized Earnings on Uncompleted Contracts	Contract assets and contract liabilities and recognized earnings consist of the following (in millions): September 30, December 31, Costs incurred on contracts in progress $ 2,098.3 $ 2,161.5 Estimated earnings 343.5 316.4 Contract revenue earned on uncompleted contracts 2,441.8 2,477.9 Less: progress billings 2,381.2 2,438.4 $ 60.6 $ 39.5 The above is included in the accompanying consolidated balance sheets under the following line items: Contract assets $ 156.0 $ 118.6 Contract liabilities (95.4) (79.1) $ 60.6 $ 39.5
Disaggregation of Revenue	The following table disaggregates DBMG's revenue by market (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Commercial $ 187.3 $ 207.0 $ 643.9 $ 343.3 Industrial 96.3 92.9 270.5 207.9 Healthcare 36.0 17.1 93.3 37.2 Convention 55.5 23.4 97.2 51.7 Transportation 15.0 16.0 32.9 40.0 Leisure 7.9 4.8 17.7 16.5 Government 10.9 15.9 27.4 54.6 Other 3.7 5.9 13.7 25.1 Total revenue from contracts with customers 412.6 383.0 1,196.6 776.3 Other revenue 0.1 — 0.4 — Total Infrastructure segment revenue $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 The following table disaggregates the Spectrum segment's revenue by type (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Broadcast station $ 4.7 $ 4.7 $ 14.2 $ 13.6 Network advertising 3.4 4.2 10.7 13.7 Network distribution 0.8 0.8 2.2 2.5 Other 0.2 0.5 0.9 1.5 Total Spectrum segment revenue $ 9.1 $ 10.2 $ 28.0 $ 31.3
Contract with Customer, Asset and Liability	Contract assets and contract liabilities consisted of the following (in millions): September 30, December 31, Cost in excess of billings $ 85.4 $ 68.3 Conditional retainage 70.6 50.3 Contract assets $ 156.0 $ 118.6 Billings in excess of costs $ (152.7) $ (137.6) Conditional retainage 57.3 58.5 Contract liabilities $ (95.4) $ (79.1)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction	As of September 30, 2022, the transaction price allocated to remaining unsatisfied performance obligations consisted of the following (in millions): Within One Year Within Five Years Total Commercial $ 409.7 $ 110.4 $ 520.1 Industrial 243.4 18.5 261.9 Transportation 332.9 97.6 430.5 Government 13.2 — 13.2 Leisure 6.6 — 6.6 Healthcare 418.9 108.9 527.8 Convention 132.0 8.0 140.0 Other 3.0 — 3.0 Remaining unsatisfied performance obligations $ 1,559.7 $ 343.4 $ 1,903.1

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Schedule of Accounts Receivable, net	Accounts receivables, net, from contracts with customers consist of the following (in millions): September 30, December 31, Accounts receivables with customers Infrastructure $ 313.9 $ 226.8 Life Sciences 0.8 0.3 Spectrum 7.1 9.4 Total accounts receivables with customers $ 321.8 $ 236.5 Accounts receivable, net consist of the following (in millions): September 30, December 31, Contracts in progress $ 313.9 $ 226.8 Unbilled retentions 0.4 0.4 Trade receivables 7.8 9.9 Other receivables 6.1 10.6 Allowance for doubtful accounts (0.3) (0.6) Total $ 327.9 $ 247.1

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in millions): September 30, December 31, Raw materials and consumables $ 17.3 $ 14.3 Work in process 0.8 1.2 Finished goods 2.6 1.5 Total inventory $ 20.7 $ 17.0

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Investments	The carrying values of the Company's investments were as follows (in millions): September 30, 2022 Measurement Alternative (1) Equity Fair Value Total Common stock $ — $ 2.9 $ — $ 2.9 Preferred stock and fixed maturities — 0.5 5.6 6.1 Put option 11.3 — — 11.3 Investment in securities — 37.4 — 37.4 Total $ 11.3 $ 40.8 $ 5.6 $ 57.7 December 31, 2021 Measurement Alternative (1) Equity Fair Value Total Common stock $ — $ 2.1 $ — $ 2.1 Preferred stock and fixed maturities 0.5 2.1 5.4 8.0 Put option 11.3 — — 11.3 Investment in securities — 34.6 — 34.6 Total $ 11.8 $ 38.8 $ 5.4 $ 56.0 (1) The Company accounts for its equity securities without readily determinable fair values under the measurement alternative election of ASC 321, whereby the Company can elect to measure an equity security without a readily determinable fair value, that does not qualify for the practical expedient to estimate fair value (net asset value), at its cost minus impairment, if any .
Summarized Information for Equity Method Investments	The following tables provide summarized financial information for the Company's equity method investments (in millions): September 30, December 31, Assets $ 645.4 $ 604.5 Liabilities 530.4 481.5 Equity $ 115.0 $ 123.0 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Total revenues $ 149.8 $ 92.0 $ 359.1 $ 390.6 Gross profit $ 23.1 $ 14.4 $ 68.0 $ 58.7 Operating income (loss) $ 2.5 $ (7.1) $ 7.9 $ (6.2) Net income (loss) $ 0.1 $ (8.4) $ 6.9 $ (8.3)

Property, Plant & Equipment, _2

Property, Plant & Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of Property, Plant, and Equipment, net	Property, plant and equipment, net, consists of the following (in millions): September 30, December 31, Equipment, furniture and fixtures, and software $ 192.1 $ 180.7 Building and leasehold improvements 44.8 43.0 Land 26.1 24.1 Construction in progress 9.3 8.9 Plant and transportation equipment 8.3 8.3 $ 280.6 $ 265.0 Less: Accumulated depreciation 112.6 95.1 Total $ 168.0 $ 169.9

Goodwill and Intangibles, Net (

Goodwill and Intangibles, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of the Changes in the Carrying Amount of Goodwill by Reporting Unit	The carrying amount of goodwill by segment was as follows (in millions): Infrastructure Spectrum Total Balance at December 31, 2021 $ 106.0 $ 21.4 $ 127.4 Translation (0.6) — (0.6) Balance as of September 30, 2022 $ 105.4 $ 21.4 $ 126.8
Schedule of Indefinite-Lived Intangible Assets	The carrying amount of indefinite-lived intangible assets was as follows (in millions): September 30, 2022 December 31, 2021 FCC licenses $ 106.4 $ 106.5 Total $ 106.4 $ 106.5
Schedule of Intangible Assets Subject to Amortization	The gross carrying amounts and accumulated amortization of definite lived intangible assets by major intangible asset class were as follows (in millions): Weighted-Average Original Useful Life September 30, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Trade names 14 years $ 25.4 $ (7.6) $ 17.8 $ 25.4 $ (6.3) $ 19.1 Customer relationships and contracts 11 years 87.5 (31.8) 55.7 87.7 (21.6) 66.1 Channel sharing arrangements 35 years 12.6 (1.4) 11.2 12.6 (1.1) 11.5 Other 12 years 4.1 (0.9) 3.2 8.5 (3.3) 5.2 Total $ 129.6 $ (41.7) $ 87.9 $ 134.2 $ (32.3) $ 101.9
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Future estimated annual amortization expense for intangible assets is as follows (in millions): Estimated Amortization 2022 $ 4.1 2023 11.0 2024 7.4 2025 7.2 2026 6.9 Thereafter 51.3 Total $ 87.9

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table presents the unaudited results of operations data for the nine months ended September 30, 2021 for Banker Steel from the date of acquisition (in millions): Nine Months Ended September 30, 2021 Revenue $ 153.8 Income from operations $ 7.3 Net income attributable to INNOVATE $ 4.5
Business Acquisition, Pro Forma Information	The following table presents unaudited consolidated pro forma results of operations data as if the acquisition of Banker Steel had occurred at the beginning of the prior period. This information does not purport to be indicative of the actual results that would have occurred if the acquisitions had actually been completed on the date indicated, nor is it necessarily indicative of the future operating results or the financial position of the combined company (in millions): Nine Months Ended September 30, 2021 Revenue $ 1,007.9 Loss from operations $ (6.0) Net loss attributable to INNOVATE $ (214.5)

Dispositions, Deconsolidation_2

Dispositions, Deconsolidations and Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Summarized Operating Results of Discontinued Operations	The results of Beyond6 and CIG and the related expenses directly attributable to the entities were reported as discontinued operations. The discontinued operations of Beyond6, and CIG are included in the Company's Other Segment. Summarized operating results of the discontinued operations are as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ — $ — $ — $ 1.7 Life, accident and health earned premiums, net — — — 55.7 Net investment income — — — 92.4 Realized/unrealized gains on investments — — — 5.1 Total revenue — — — 154.9 Cost of revenue — — — 0.8 Policy benefits, changes in reserves, and commissions — — — 126.0 Selling, general and administrative — — — 21.1 Depreciation and amortization — — — (11.0) Income from operations — — — 18.0 Interest expense — — — (0.5) Loss on sale and liquidation of subsidiaries — (200.3) — (159.9) Other loss — — — (3.1) Pre-tax loss from discontinued operations — (200.3) — (145.5) Income tax expense — — — (4.4) Loss from discontinued operations $ — $ (200.3) $ — $ (149.9)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Lease ROUs and Lease Liabilities	As of September 30, 2022 and December 31, 2021, lease right-of-use assets and lease liabilities consist of the following (in millions): September 30, December 31, Right-of-use assets: Operating lease (Other assets) $ 65.7 $ 69.6 Finance lease (Property, plant and equipment, net) 2.2 0.2 Total right-of-use assets $ 67.9 $ 69.8 Lease liabilities: Current portion of operating lease (Other current liabilities) $ 17.3 $ 15.5 Non-current portion of operating lease (Other liabilities) 53.2 58.5 Finance lease (Debt obligations) 2.2 0.1 Total lease liabilities $ 72.7 $ 74.1
Schedule of Leases, Cost	The following table summarizes the components of lease expense (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.2 $ 0.2 $ 0.8 Interest on lease liabilities — — — — Net finance lease cost 0.1 0.2 0.2 0.8 Operating lease cost 5.8 7.9 17.6 15.7 Variable lease cost 0.1 0.1 0.4 0.3 Sublease income (0.1) — (0.5) — Total lease cost $ 5.9 $ 8.2 $ 17.7 $ 16.8 Cash flow information related to leases is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases $ — $ 0.1 $ 0.1 $ 0.6 Operating cash flows from operating leases $ 5.6 $ 8.1 $ 17.6 $ 16.0 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1.7 $ — $ 2.2 $ — Operating leases $ 2.8 $ 1.7 $ 10.5 $ 42.9 The weighted-average remaining lease term and the weighted-average discount rate for finance leases and operating leases for the periods presented are as follows: September 30, December 31, Weighted-average remaining lease term (years) - operating lease 7.5 7.5 Weighted-average remaining lease term (years) - finance lease 1.6 2.3 Weighted-average discount rate - operating lease 5.4 % 5.4 % Weighted-average discount rate - finance lease 5.6 % 4.2 %
Schedule of Finance Lease, Liability, Maturity	As of September 30, 2022, undiscounted cash flows for finance and operating leases are as follows (in millions): Operating Finance 2022 $ 5.1 $ 0.1 2023 19.2 1.8 2024 13.4 0.3 2025 10.0 0.1 2026 6.8 — Thereafter 31.6 — Total future lease payments 86.1 2.3 Less: Present values (15.6) (0.1) Total lease liability balance $ 70.5 $ 2.2
Schedule of Operating Lease, Liability, Maturity	As of September 30, 2022, undiscounted cash flows for finance and operating leases are as follows (in millions): Operating Finance 2022 $ 5.1 $ 0.1 2023 19.2 1.8 2024 13.4 0.3 2025 10.0 0.1 2026 6.8 — Thereafter 31.6 — Total future lease payments 86.1 2.3 Less: Present values (15.6) (0.1) Total lease liability balance $ 70.5 $ 2.2

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets, which are reflected in non-current assets in the Condensed Consolidated Balance Sheets, consist of the following (in millions): September 30, December 31, Right-of-use assets $ 65.7 $ 69.6 Restricted cash - non-current 1.5 — Other 4.2 3.7 Total other assets $ 71.4 $ 73.3

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in millions): September 30, December 31, Accrued expenses and other current liabilities $ 21.7 $ 24.5 Accrued payroll and employee benefits 40.4 38.9 Accrued interest 25.8 29.6 Accrued income taxes 0.3 0.4 Total accrued liabilities $ 88.2 $ 93.4

Debt Obligations (Tables)

Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt and Finance Lease Obligations	Debt obligations consist of the following (in millions): September 30, December 31, Infrastructure 3.25% Note due 2026 $ 101.0 $ 107.2 PRIME minus 0.85% Line of Credit due 2024 107.7 30.4 4.00% Note due 2024 17.5 25.0 8.00% Note due 2024 19.1 19.6 11.00% Note due 2024 — 6.3 Obligations under finance leases 2.2 0.1 Spectrum 8.50% Note due 2022 19.3 19.3 10.50% Note due 2022 32.9 32.9 Life Sciences 12.00% Note due 2022 10.0 — Non-Operating Corporate 8.50% Senior Secured Notes, due 2026 330.0 330.0 7.50% Convertible Senior Notes, due 2026 51.8 51.8 7.50% Convertible Senior Notes, due 2022 — 3.2 LIBOR plus 5.75% Line of Credit due 2024 20.0 5.0 711.5 630.8 Unamortized issuance discount, issuance premium, and deferred financing costs (2.2) (4.5) Less: current portion of debt obligations (81.4) (69.5) Debt obligations $ 627.9 $ 556.8
Schedule of Maturities of Debt and Finance Lease Obligations	Aggregate finance lease and debt payments, including interest, are as follows (in millions): Finance Leases Debt Total 2022 $ 0.1 $ 79.2 $ 79.3 2023 1.8 62.3 64.1 2024 0.3 194.2 194.5 2025 0.1 41.2 41.3 2026 — 469.8 469.8 Thereafter — — — Total minimum principal and interest payments 2.3 846.7 849.0 Less: Amount representing interest (0.1) (137.4) (137.5) Total aggregate finance lease and debt payments $ 2.2 $ 709.3 $ 711.5

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Schedule of Other Liabilities	Other liabilities, which are reflected in non-current liabilities in the Condensed Consolidated Balance Sheets, consist of the following (in millions): September 30, December 31, Lease liability, net of current portion $ 53.2 $ 58.5 Other 4.4 4.8 Total other liabilities $ 57.6 $ 63.3

Share-based Compensation (Table

Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Company's Restricted Stock Activity	A summary of INNOVATE’s restricted stock activity is as follows: Shares Weighted Average Grant Date Fair Value Unvested - December 31, 2020 628,433 $ 3.93 Granted 593,458 $ 3.81 Vested (514,543) $ 3.89 Forfeited (151,469) $ 4.13 Unvested - December 31, 2021 555,879 $ 3.79 Granted 599,797 $ 3.57 Vested (292,091) $ 3.81 Forfeited (45,289) $ 3.68 Unvested - September 30, 2022 818,296 $ 3.63
Summary of Company's Stock Option Activity	A summary of INNOVATE’s stock option activity is as follows: Shares Weighted Average Exercise Price Outstanding - December 31, 2020 4,739,858 $ 5.13 Expired (23,999) $ 5.31 Outstanding - December 31, 2021 4,715,859 $ 5.13 Granted 280,791 $ 3.25 Exercised — — Forfeited — — Expired (1,500) $ 4.06 Outstanding - September 30, 2022 4,995,150 $ 5.02 Eligible for exercise 4,995,150 $ 5.02

Temporary Equity (Tables)

Temporary Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Stock by Class	The Company’s preferred shares authorized, issued and outstanding consisted of the following: September 30, December 31, Preferred shares authorized, $0.001 par value 20,000,000 20,000,000 Series A-3 shares issued and outstanding 6,125 6,125 Series A-4 shares issued and outstanding 10,000 10,000
Summary of Cash, PIK and Special Cash Dividends	During the nine months ended September 30, 2022 and 2021, INNOVATE's Board of Directors (the "Board") declared cash dividends with respect to INNOVATE’s issued and outstanding Preferred Stock, excluding the Series A and Series A-2 Preferred Stock which was owned by CGIC and was eliminated in consolidation prior to the sale of the Insurance segment on July 1, 2021, as presented in the following table (in millions): 2022 Declaration Date March 31, 2022 June 30, 2022 September 30, 2022 Holders of Record Date March 31, 2022 June 30, 2022 September 30, 2022 Payment Date April 15, 2022 July 15, 2022 October 15, 2022 Total Dividend $ 0.3 $ 0.3 $ 0.3 2021 Declaration Date March 31, 2021 May 29, 2021 September 30, 2021 Holders of Record Date March 31, 2021 May 29, 2021 September 30, 2021 Payment Date April 15, 2021 June 4, 2021 October 15, 2021 Total Dividend $ 0.2 $ 0.1 $ 0.3 During the nine months ending September 30, 2022 and 2021, DBMGi's Board of Directors declared dividends with respect to DBMGi’s issued and outstanding Preferred Stock, as presented in the following table (in millions): 2022 Declaration Date March 31, 2022 June 30, 2022 September 30, 2022 Holders of Record Date March 31, 2022 June 30, 2022 September 30, 2022 Payment Date April 15, 2022 July 15, 2022 October 15, 2022 Total Dividend* $ 0.9 $ 0.9 $ 0.9 *The dividends paid on April 15, 2022 and October 15, 2022 were paid in cash. The DBMGi Board of Directors elected to pay the second quarter dividend payable July 15, 2022 in shares. 2021 Declaration Date September 30, 2021 Holders of Record Date September 30, 2021 Payment Date October 15, 2021 Total Dividend $ 0.8

Operating Segments and Relate_2

Operating Segments and Related Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedules of Concentration of Risk, by Risk Factor	The Company's revenue concentrations of 10% and greater are as follows: Three Months Ended September 30, Nine Months Ended September 30, Segment 2022 2021 2022 2021 Customer A Infrastructure 25.2% 18.9% 24.2% 12.2% Customer B Infrastructure * 13.0% * * Customer C Infrastructure 10.1% * * * *Less than 10% revenue concentration
Summary of Company's Operating Segments	Summarized financial information with respect to the Company’s operating segments is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue Infrastructure $ 412.7 $ 383.0 $ 1,197.0 $ 776.3 Life Sciences 1.2 1.6 3.0 2.8 Spectrum 9.1 10.2 28.0 31.3 Total revenue $ 423.0 $ 394.8 $ 1,228.0 $ 810.4 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Income (loss) from operations Infrastructure $ 18.5 $ 12.6 $ 42.2 $ 17.0 Life Sciences (5.5) (4.9) (15.7) (14.2) Spectrum (0.6) (1.2) (4.1) (1.0) Other (0.3) (1.0) (0.4) (1.6) Non-operating Corporate (5.5) (4.4) (15.1) (17.7) Total income (loss) from operations $ 6.6 $ 1.1 $ 6.9 $ (17.5) A reconciliation of the Company's consolidated segment operating income (loss) to consolidated loss from continuing operations before income taxes is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Income (loss) from operations $ 6.6 $ 1.1 $ 6.9 $ (17.5) Interest expense (13.3) (12.8) (38.4) (46.6) Loss on early extinguishment or restructuring of debt — (0.1) — (12.5) Loss from equity investees (1.1) (2.9) (2.1) (4.8) Other (expense) income, net (0.9) 0.6 0.5 4.4 Loss from continuing operations before income taxes $ (8.7) $ (14.1) $ (33.1) $ (77.0) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Depreciation and Amortization Infrastructure $ 5.3 $ 7.4 $ 15.9 $ 13.1 Infrastructure recognized within cost of revenue 3.9 3.4 11.2 8.4 Total Infrastructure 9.2 10.8 27.1 21.5 Life Sciences 0.1 — 0.2 0.1 Spectrum 1.4 1.4 4.4 4.3 Non-operating Corporate — 0.1 0.1 0.1 Total depreciation and amortization $ 10.7 $ 12.3 $ 31.8 $ 26.0 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Capital Expenditures (*) Infrastructure $ 6.9 $ 6.1 $ 13.5 $ 11.6 Life Sciences 0.2 — 0.3 0.5 Spectrum 0.4 0.9 2.5 2.9 Total $ 7.5 $ 7.0 $ 16.3 $ 15.0 (*) The above capital expenditures exclude assets acquired under terms of capital lease and vendor financing obligations.
Segment Reporting for Long-term investments, Property and Equipment - Net and Assets	September 30, December 31, Investments Infrastructure $ — $ 0.7 Life Sciences 9.0 10.2 Other 48.7 45.1 Total $ 57.7 $ 56.0 September 30, December 31, Equity Method Investments (included in Investments above) Infrastructure $ — $ 0.7 Life Sciences 3.4 4.2 Other 37.4 33.9 Total $ 40.8 $ 38.8 September 30, December 31, Total Assets Infrastructure $ 893.3 $ 786.4 Life Sciences 18.8 22.0 Spectrum 191.0 198.9 Other 50.4 48.0 Non-operating Corporate 11.7 25.3 Total $ 1,165.2 $ 1,080.6

Basic and Diluted Loss Per Co_2

Basic and Diluted Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Calculation of Basic Income (Loss) Per Common Share to Diluted Income (Loss) Per Common Share	The following table presents a reconciliation of net loss used in the basic and diluted EPS calculations (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Loss from continuing operations $ (6.7) $ (14.2) $ (34.7) $ (80.8) Loss from continuing operations attributable to noncontrolling interest and redeemable noncontrolling interest 1.3 2.6 4.5 7.0 Loss from continuing operations attributable to INNOVATE Corp. (5.4) (11.6) (30.2) (73.8) Less: Preferred dividends and deemed dividends from conversions 1.2 1.1 3.6 1.7 Loss from continuing operations attributable to INNOVATE common stockholders (6.6) (12.7) (33.8) (75.5) Loss from discontinued operations — (200.3) — (149.9) Loss from discontinued operations attributable to noncontrolling interest and redeemable noncontrolling interest — — — 0.9 Loss from discontinued operations, net of tax and noncontrolling interest — (200.3) — (149.0) Net loss attributable to common stock and participating preferred stockholders $ (6.6) $ (213.0) $ (33.8) $ (224.5) Earnings allocable to common shares: Participating shares at end of period: Weighted-average common stock outstanding 77.6 77.2 77.5 77.0 Unvested restricted stock — — — — Preferred stock (as-converted basis) — — — — Total 77.6 77.2 77.5 77.0 Percentage of loss allocated to: Common stock 100.0 % 100.0 % 100.0 % 100.0 % Unvested restricted stock — % — % — % — % Preferred stock — % — % — % — % Numerator for loss per share, basic: Net loss from continuing operations attributable to common stock, basic $ (6.6) $ (12.7) $ (33.8) $ (75.5) Net loss from discontinued operations attributable to common stock, basic — (200.3) — (149.0) Net loss attributable to common stock, basic $ (6.6) $ (213.0) $ (33.8) $ (224.5) Earnings allocable to common shares, diluted: Numerator for loss per share, diluted Net loss from continuing operations attributable to common stock, basic $ (6.6) $ (12.7) $ (33.8) $ (75.5) Net loss from discontinued operations attributable to common stock, basic — (200.3) — (149.0) Net loss attributable to common stock, basic $ (6.6) $ (213.0) $ (33.8) $ (224.5) Denominator for basic and dilutive loss per share Weighted average common shares outstanding - basic 77.6 77.2 77.5 77.0 Effect of assumed shares under treasury stock method for stock options and restricted shares and if-converted method for convertible instruments — — — — Weighted average common shares outstanding - diluted 77.6 77.2 77.5 77.0 Loss per share - continuing operations Basic $ (0.09) $ (0.16) $ (0.44) $ (0.98) Diluted $ (0.09) $ (0.16) $ (0.44) $ (0.98) Loss per share - discontinued operations Basic $ — $ (2.59) $ — $ (1.94) Diluted $ — $ (2.59) $ — $ (1.94) Loss per share - Net loss attributable to common stock and participating preferred stockholders Basic $ (0.09) $ (2.75) $ (0.44) $ (2.92) Diluted $ (0.09) $ (2.75) $ (0.44) $ (2.92)

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Instruments Measured at Fair Value on Nonrecurring Basis	The following table presents the carrying amounts and estimated fair values of the Company’s financial instruments, which were not measured at fair value on a recurring basis. The table excludes carrying amounts for cash and cash equivalents and restricted cash, accounts receivable and contract assets, accounts payable, contract liabilities and other current liabilities, and other assets and liabilities that approximate fair value due to relatively short periods to maturity (in millions): September 30, 2022 Fair Value Measurement Using: Carrying Value Estimated Fair Value Level 1 Level 2 Level 3 Assets Other invested assets $ 11.3 $ 11.3 $ — $ — $ 11.3 Total assets not accounted for at fair value $ 11.3 $ 11.3 $ — $ — $ 11.3 Liabilities Debt obligations (1) $ 707.1 $ 637.5 $ — $ 637.5 $ — Total liabilities not accounted for at fair value $ 707.1 $ 637.5 $ — $ 637.5 $ — December 31, 2021 Fair Value Measurement Using: Carrying Value Estimated Fair Value Level 1 Level 2 Level 3 Assets Other invested assets $ 11.3 $ 11.3 $ — $ — $ 11.3 Total assets not accounted for at fair value $ 11.3 $ 11.3 $ — $ — $ 11.3 Liabilities Debt obligations (1) $ 626.3 $ 648.2 $ — $ 648.2 $ — Total liabilities not accounted for at fair value $ 626.3 $ 648.2 $ — $ 648.2 $ — (1) Excludes operating lease obligations accounted for under ASC 842, Leases .

Supplementary Financial Infor_2

Supplementary Financial Information (Tables)	9 Months Ended
	Sep. 30, 2022
Offsetting [Abstract]
Schedule of Restricted Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions): September 30, 2022 2021 Cash and cash equivalents, beginning of period $ 45.5 $ 43.8 Restricted cash 2.0 1.5 Restricted cash included in other assets (non-current) — — Total cash, cash equivalents and restricted cash $ 47.5 $ 45.3 Cash and cash equivalents, end of period $ 25.8 $ 55.5 Restricted cash 0.4 8.6 Restricted cash included in other assets (non-current) 1.5 — Total cash and cash equivalents and restricted cash $ 27.7 $ 64.1 Cash and cash equivalents classified in Assets held for sale, beginning of period $ — $ 195.2 Restricted cash classified in Assets held for sale — 0.2 Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ 195.4 Cash and cash equivalents classified in Assets held for sale, end of period $ — $ — Restricted cash classified in Assets held for sale — — Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ — Supplemental cash flow information: Cash paid for interest $ 38.9 $ 31.3 Cash paid for taxes, net of refunds $ 3.8 $ 4.3 Non-cash investing and financing activities: Property, plant and equipment included in accounts payable $ 0.9 $ 2.1 Issuance of preferred stock $ 0.9 $ 19.1 Issuance of redeemable noncontrolling interest $ — $ 40.9 Extinguishment of convertible note in exchange $ — $ 51.8 Issuance of convertible note in exchange $ — $ (51.8) Debt assumed in acquisitions $ — $ 6.3
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows (in millions): September 30, 2022 2021 Cash and cash equivalents, beginning of period $ 45.5 $ 43.8 Restricted cash 2.0 1.5 Restricted cash included in other assets (non-current) — — Total cash, cash equivalents and restricted cash $ 47.5 $ 45.3 Cash and cash equivalents, end of period $ 25.8 $ 55.5 Restricted cash 0.4 8.6 Restricted cash included in other assets (non-current) 1.5 — Total cash and cash equivalents and restricted cash $ 27.7 $ 64.1 Cash and cash equivalents classified in Assets held for sale, beginning of period $ — $ 195.2 Restricted cash classified in Assets held for sale — 0.2 Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ 195.4 Cash and cash equivalents classified in Assets held for sale, end of period $ — $ — Restricted cash classified in Assets held for sale — — Total cash and cash equivalents and restricted cash classified in Assets held for sale $ — $ — Supplemental cash flow information: Cash paid for interest $ 38.9 $ 31.3 Cash paid for taxes, net of refunds $ 3.8 $ 4.3 Non-cash investing and financing activities: Property, plant and equipment included in accounts payable $ 0.9 $ 2.1 Issuance of preferred stock $ 0.9 $ 19.1 Issuance of redeemable noncontrolling interest $ — $ 40.9 Extinguishment of convertible note in exchange $ — $ 51.8 Issuance of convertible note in exchange $ — $ (51.8) Debt assumed in acquisitions $ — $ 6.3

Organization and Business (Deta

Organization and Business (Details)	9 Months Ended
	Sep. 30, 2022 segment
Business And Organization [Line Items]
Number of reportable segments	3
DBMG
Business And Organization [Line Items]
Parents interest, controlling (approximately)	91%
Genoval Orthopedics inc.
Business And Organization [Line Items]
Parents interest, controlling (approximately)	80%
R2 Technologies, Inc.
Business And Organization [Line Items]
Parents interest, controlling (approximately)	56%
MediBeacon Inc.
Business And Organization [Line Items]
Parents interest, controlling (approximately)	47%
Triple Ring
Business And Organization [Line Items]
Parents interest, controlling (approximately)	26%
HC2 Broadcasting Holdings, Inc
Business And Organization [Line Items]
Parents interest, controlling (approximately)	98%
DTV America
Business And Organization [Line Items]
Parents interest, controlling (approximately)	77%
Minority Holders
Business And Organization [Line Items]
Percentage of proxy and voting rights from minority holders	10%
GMSL
Business And Organization [Line Items]
Parents interest, controlling (approximately)	73%
HMN
Business And Organization [Line Items]
Parents interest, controlling (approximately)	19%

Revenue and Contracts in Proc_3

Revenue and Contracts in Process - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Infrastructure
Segment Reporting Information [Line Items]
Revenue	412.6	383	1,196.6	776.3
Life Sciences
Segment Reporting Information [Line Items]
Revenue	1.2	1.6	3	2.8
Spectrum
Segment Reporting Information [Line Items]
Revenue	9.1	10.2	28	31.3
Operating Segments | Infrastructure
Segment Reporting Information [Line Items]
Revenue	412.7	383	1,197	776.3
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenue	1.2	1.6	3	2.8
Operating Segments | Spectrum
Segment Reporting Information [Line Items]
Revenue	$ 9.1	$ 10.2	$ 28	$ 31.3

Revenue and Contracts in Proc_4

Revenue and Contracts in Process - Schedule of Accounts Receivable (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total accounts receivables with customers	$ 321.8	$ 236.5
Infrastructure
Segment Reporting Information [Line Items]
Total accounts receivables with customers	313.9	226.8
Life Sciences
Segment Reporting Information [Line Items]
Total accounts receivables with customers	0.8	0.3
Spectrum
Segment Reporting Information [Line Items]
Total accounts receivables with customers	$ 7.1	$ 9.4

Revenue and Contracts in Proc_5

Revenue and Contracts in Process - Contract Assets and Contract Liabilities and Recognized Earnings (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Costs incurred on contracts in progress	$ 2,098.3	$ 2,161.5
Estimated earnings	343.5	316.4
Contract revenue earned on uncompleted contracts	2,441.8	2,477.9
Less: progress billings	2,381.2	2,438.4
Net of cost earned on uncompleted contracts	60.6	39.5
The above is included in the accompanying consolidated balance sheets under the following line items:
Contract assets	156	118.6
Contract liabilities	(95.4)	(79.1)
Net contract assets (liabilities)	$ 60.6	$ 39.5

Revenue and Contracts in Proc_6

Revenue and Contracts in Process - Infrastructure Segment Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Total Infrastructure segment revenue	423	394.8	1,228	810.4
Infrastructure
Disaggregation of Revenue [Line Items]
Revenue	412.6	383	1,196.6	776.3
Other revenue	0.1	0	0.4	0
Total Infrastructure segment revenue	412.7	383	1,197	776.3
Infrastructure | Commercial
Disaggregation of Revenue [Line Items]
Revenue	187.3	207	643.9	343.3
Infrastructure | Industrial
Disaggregation of Revenue [Line Items]
Revenue	96.3	92.9	270.5	207.9
Infrastructure | Healthcare
Disaggregation of Revenue [Line Items]
Revenue	36	17.1	93.3	37.2
Infrastructure | Convention
Disaggregation of Revenue [Line Items]
Revenue	55.5	23.4	97.2	51.7
Infrastructure | Transportation
Disaggregation of Revenue [Line Items]
Revenue	15	16	32.9	40
Infrastructure | Leisure
Disaggregation of Revenue [Line Items]
Revenue	7.9	4.8	17.7	16.5
Infrastructure | Government
Disaggregation of Revenue [Line Items]
Revenue	10.9	15.9	27.4	54.6
Infrastructure | Other
Disaggregation of Revenue [Line Items]
Revenue	$ 3.7	$ 5.9	$ 13.7	$ 25.1

Revenue and Contracts in Proc_7

Revenue and Contracts in Process - Infrastructure Segment Contract with Customer, Asset and Liability (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Contract assets	$ 156	$ 118.6
Contract liabilities	(95.4)	(79.1)
Infrastructure
Segment Reporting Information [Line Items]
Cost in excess of billings	85.4	68.3
Conditional retainage	70.6	50.3
Contract assets	156	118.6
Billings in excess of costs	(152.7)	(137.6)
Conditional retainage	57.3	58.5
Contract liabilities	$ (95.4)	$ (79.1)

Revenue and Contracts in Proc_8

Revenue and Contracts in Process - Narrative (Details) - Infrastructure $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Revenue from External Customer [Line Items]
Contract assets, increase due to new projects	$ 171.4
Contract assets, reclassified to receivables	134
Contract liabilities, increase due to new projects	93.2
Contract liabilities, revenue recognized	$ 76.9

Revenue and Contracts in Proc_9

Revenue and Contracts in Process - Schedule of Infrastructure Segment Revenue (Details) - Infrastructure $ in Millions	Sep. 30, 2022 USD ($)
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1,903.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | DBMG
Segment Reporting Information [Line Items]
Remaining performance obligation period	36 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 1,559.7
Remaining performance obligation period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 343.4
Remaining performance obligation period	5 years
Commercial
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 520.1
Commercial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 409.7
Remaining performance obligation period	1 year
Commercial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 110.4
Remaining performance obligation period	5 years
Industrial
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 261.9
Industrial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 243.4
Remaining performance obligation period	1 year
Industrial | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 18.5
Remaining performance obligation period	5 years
Transportation
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 430.5
Transportation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 332.9
Remaining performance obligation period	1 year
Transportation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 97.6
Remaining performance obligation period	5 years
Government
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 13.2
Government | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 13.2
Remaining performance obligation period	1 year
Government | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 0
Remaining performance obligation period	5 years
Leisure
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 6.6
Leisure | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 6.6
Remaining performance obligation period	1 year
Leisure | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 0
Remaining performance obligation period	5 years
Healthcare
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 527.8
Healthcare | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 418.9
Remaining performance obligation period	1 year
Healthcare | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 108.9
Remaining performance obligation period	5 years
Convention
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 140
Convention | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 132
Remaining performance obligation period	1 year
Convention | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 8
Remaining performance obligation period	5 years
Other
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 3
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 3
Remaining performance obligation period	1 year
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Segment Reporting Information [Line Items]
Remaining performance obligations	$ 0
Remaining performance obligation period	5 years

Revenue and Contracts in Pro_10

Revenue and Contracts in Process - Life Sciences Segment Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total Life Sciences segment revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Life Sciences
Segment Reporting Information [Line Items]
Total Life Sciences segment revenue	1.2	1.6	3	2.8
Systems and consumables revenue | Life Sciences
Segment Reporting Information [Line Items]
Total Life Sciences segment revenue	$ 1.2	$ 1.6	$ 3	$ 2.8

Revenue and Contracts in Pro_11

Revenue and Contracts in Process - Spectrum Segment Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Spectrum
Segment Reporting Information [Line Items]
Revenue	9.1	10.2	28	31.3
Broadcast station | Spectrum
Segment Reporting Information [Line Items]
Revenue	4.7	4.7	14.2	13.6
Network advertising | Spectrum
Segment Reporting Information [Line Items]
Revenue	3.4	4.2	10.7	13.7
Network distribution | Spectrum
Segment Reporting Information [Line Items]
Revenue	0.8	0.8	2.2	2.5
Other | Spectrum
Segment Reporting Information [Line Items]
Revenue	$ 0.2	$ 0.5	$ 0.9	$ 1.5

Revenue and Contracts in Pro_12

Revenue and Contracts in Process - Remaining Unsatisfied Performance Obligations (Details) - Spectrum $ in Millions	Sep. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Within One Year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 2.8
Remaining performance obligation period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Within Five Years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 0.8
Remaining performance obligation period	36 months
Broadcast station | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 3.4
Network advertising | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	0.1
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 0.1

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Contracts in progress	$ 313.9	$ 226.8
Unbilled retentions	0.4	0.4
Trade receivables	7.8	9.9
Other receivables	6.1	10.6
Allowance for doubtful accounts	(0.3)	(0.6)
Total	$ 327.9	$ 247.1

Inventory (Details)

Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials and consumables	$ 17.3	$ 14.3
Work in process	0.8	1.2
Finished goods	2.6	1.5
Total inventory	$ 20.7	$ 17

Investments - Schedule of Compa

Investments - Schedule of Company Investments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Measurement Alternative	$ 11.3	$ 11.8
Equity Method	40.8	38.8
Fair Value	5.6	5.4
Investments	57.7	56
Common stock
Schedule of Equity Method Investments [Line Items]
Measurement Alternative	0	0
Equity Method	2.9	2.1
Fair Value	0	0
Investments	2.9	2.1
Preferred stock and fixed maturities
Schedule of Equity Method Investments [Line Items]
Measurement Alternative	0	0.5
Equity Method	0.5	2.1
Fair Value	5.6	5.4
Investments	6.1	8
Put option
Schedule of Equity Method Investments [Line Items]
Measurement Alternative	11.3	11.3
Equity Method	0	0
Fair Value	0	0
Investments	11.3	11.3
Investment in securities
Schedule of Equity Method Investments [Line Items]
Measurement Alternative	0	0
Equity Method	37.4	34.6
Fair Value	0	0
Investments	$ 37.4	$ 34.6

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule of Equity Method Investments [Line Items]
Loss from equity investees	$ (1.1)	$ (2.9)	$ (2.1)	$ (4.8)
MediBeacon Inc. | Convertible Debt | Life Sciences
Schedule of Equity Method Investments [Line Items]
Face amount	$ 4.5		$ 4.5
Interest rate	8%		8%
Outstanding debt	$ 5		$ 5

Investments - Summarized Inform

Investments - Summarized Information for Equity Method Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Assets	$ 1,165.2		$ 1,165.2			$ 1,080.6
Liabilities	1,193.8		1,193.8			1,068.7
Equity	(91.5)	$ (54.7)	(91.5)	$ (54.7)	$ (84.1)	(56.2)	$ 511.5	$ 600.2
Total revenues	423	394.8	1,228	810.4
Gross profit	58.4	55.1	158.5	122
Operating income (loss)	(5.4)	(11.6)	(30.2)	(73.8)
Net income (loss)	(5.4)	(211.9)	(30.2)	(222.8)
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule of Equity Method Investments [Line Items]
Assets	645.4		645.4			604.5
Liabilities	530.4		530.4			481.5
Equity	115		115			$ 123
Total revenues	149.8	92	359.1	390.6
Gross profit	23.1	14.4	68	58.7
Operating income (loss)	2.5	(7.1)	7.9	(6.2)
Net income (loss)	$ 0.1	$ (8.4)	$ 6.9	$ (8.3)

Property, Plant & Equipment, _3

Property, Plant & Equipment, Net - Summary of Property, Plant, and Equipment, net (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	$ 280.6	$ 265
Less: Accumulated depreciation	112.6	95.1
Total	168	169.9
Equipment, furniture and fixtures, and software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	192.1	180.7
Building and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	44.8	43
Land
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	26.1	24.1
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	9.3	8.9
Plant and transportation equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment and finance lease right-of-use asset, gross	$ 8.3	$ 8.3

Property, Plant & Equipment, _4

Property, Plant & Equipment, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 6.6	$ 7.8	$ 19.3	$ 17.7
Net book value of equipment under capital leases	2.2		2.2		$ 0.2
Operating Segments
Property, Plant and Equipment [Line Items]
Depreciation expense within cost of revenue	$ 3.9	$ 3.4	$ 11.2	$ 8.4

Goodwill and Intangibles, Net -

Goodwill and Intangibles, Net - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 127.4
Translation	(0.6)
Ending balance	126.8
Infrastructure
Goodwill [Roll Forward]
Beginning balance	106
Translation	(0.6)
Ending balance	105.4
Spectrum
Goodwill [Roll Forward]
Beginning balance	21.4
Translation	0
Ending balance	$ 21.4

Goodwill and Intangibles, Net_2

Goodwill and Intangibles, Net - Indefinite-lived Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 106.4	$ 106.5
FCC licenses
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 106.4	$ 106.5

Goodwill and Intangibles, Net_3

Goodwill and Intangibles, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Impairment definite lived intangible assets			$ 1.5
Amortization expense	$ 4.1	$ 4.5	12.5	$ 8.3
Non-core FCC Licenses
Finite-Lived Intangible Assets [Line Items]
Intangible assets, impairment charges			$ 0.1	$ 2.7

Goodwill and Intangibles, Net_4

Goodwill and Intangibles, Net - Definite Lived Intangible Assets (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 129.6	$ 134.2
Accumulated Amortization	(41.7)	(32.3)
Net	$ 87.9	101.9
Trade names
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	14 years
Gross Carrying Amount	$ 25.4	25.4
Accumulated Amortization	(7.6)	(6.3)
Net	$ 17.8	19.1
Customer relationships and contracts
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	11 years
Gross Carrying Amount	$ 87.5	87.7
Accumulated Amortization	(31.8)	(21.6)
Net	$ 55.7	66.1
Channel sharing arrangements
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	35 years
Gross Carrying Amount	$ 12.6	12.6
Accumulated Amortization	(1.4)	(1.1)
Net	$ 11.2	11.5
Other
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Original Useful Life	12 years
Gross Carrying Amount	$ 4.1	8.5
Accumulated Amortization	(0.9)	(3.3)
Net	$ 3.2	$ 5.2

Goodwill and Intangibles, Net_5

Goodwill and Intangibles, Net - Estimated Amortization Expense (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Estimated Amortization
2022	$ 4.1
2023	11
2024	7.4
2025	7.2
2026	6.9
Thereafter	51.3
Net	$ 87.9	$ 101.9

Acquisitions - Infrastructure S

Acquisitions - Infrastructure Segment Narrative (Details)		9 Months Ended
	May 27, 2021 USD ($) company	Sep. 30, 2022 segment
Business Acquisition [Line Items]
Number of reportable operating segments | segment		3
Banker Steel Acquisition
Business Acquisition [Line Items]
Percentage of business acquired	100%
Consideration transferred	$ 145,000,000
Bankers Steel debt - assumed	6,300,000
Cash acquired from acquisition	$ 25,000,000
Number of reportable operating segments | company	6
Banker Steel Acquisition | Sellers' Notes
Business Acquisition [Line Items]
Face amount	$ 49,600,000
Banker Steel Acquisition | Revolving Credit Facility
Business Acquisition [Line Items]
Face amount	64,100,000
Banker Steel Acquisition | Term Loan
Business Acquisition [Line Items]
Face amount	$ 110,000,000

Acquisitions - Results of Opera

Acquisitions - Results of Operations and Pro Forma Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition [Line Items]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Income from operations	(6.7)	(14.2)	(34.7)	(80.8)
Net income attributable to INNOVATE	$ (5.4)	$ (211.9)	$ (30.2)	(222.8)
Banker Steel Acquisition
Business Acquisition [Line Items]
Revenue				153.8
Income from operations				7.3
Net income attributable to INNOVATE				4.5
Banker Steel Acquisition
Business Acquisition [Line Items]
Revenue				1,007.9
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax				(6)
Business Acquisition, Pro Forma Net Income (Loss)				$ (214.5)

Dispositions, Deconsolidation_3

Dispositions, Deconsolidations and Discontinued Operations - Narrative (Details) - USD ($)						3 Months Ended						9 Months Ended
	Oct. 11, 2022	Feb. 23, 2021	Jan. 15, 2021	Feb. 28, 2020	Jan. 30, 2020	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 01, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated other comprehensive income							$ 2,900,000					$ 2,900,000		$ 6,400,000
Cash and cash equivalents							25,800,000	$ 55,500,000		$ 43,800,000		25,800,000	$ 55,500,000	45,500,000
Investments							57,700,000					57,700,000		56,000,000
Gain on sale of subsidiary													(159,900,000)
Income tax expense (benefit)							(2,000,000)	100,000				1,600,000	3,800,000
Repayments of long-term debt												23,700,000	454,800,000
Cash received from dispositions, net of cash disposed												0	74,000,000
Loss on disposal of subsidiary							0	334,000,000				0	334,000,000
New Saxon 2019 Limited
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Parents interest, controlling (approximately)					73%
Non-Operating Corporate | LIBOR plus 5.75% Line of Credit due 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Basis spread on variable rate		6.75%
Beyond6
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration to be received										106,500,000
Proceeds from divestiture of businesses			$ 70,000,000
Beyond6 | 2020 Revolving Credit Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of long-term debt			15,000,000
Beyond6 | 2021 Senior Secured Notes
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of long-term debt			$ 27,900,000
GMSL
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of subsidiary									$ 1,200,000	$ 2,400,000	$ (39,300,000)
Consideration to be received					$ 250,000,000
Proceeds from divestiture of businesses				$ 144,000,000
Ownership percentage before sale of stock					100%
Potential earn-out, maximum					$ 12,500,000
Cash received from dispositions, net of cash disposed				100,800,000
Consideration held in escrow for future losses payable				1,250,000
Consideration held of escrow for purchase price adjustment				1,910,000
Consideration paid after closing				2,400,000
Loss on disposal of subsidiary											31,300,000
Actuarial losses on pension											17,200,000
Currency translation adjustments											$ 14,100,000
GMSL | Non- controlling Interest
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash divested from deconsolidation				36,800,000
GMSL | Noncontrolling Interest Redeemable
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash divested from deconsolidation				$ 5,500,000
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of subsidiary							0	(200,300,000)				0	$ (159,900,000)
Other current assets classified in assets held for sale							0					0		$ 1,500,000
Discontinued Operations | CIG
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of subsidiary								(200,800,000)
Current income tax expense (Benefit)												2,900,000
Discontinued Operations | CIG | Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax expense (benefit)						$ 1,200,000
Discontinued Operations | CIG | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of subsidiary	$ (1,700,000)
Discontinued Operations | CIG | CGI
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax expense (benefit)							$ 2,900,000					$ 2,900,000
Discontinued Operations | CIG | CGI | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deemed contribution tax received	$ 1,700,000
Discontinued Operations | CIG | Insurance Services
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Segment book value															$ 544,000,000
Accumulated other comprehensive income															344,000,000
Cash and cash equivalents															62,500,000
Investments															$ 26,700,000
Discontinued Operations | Beyond6
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of subsidiary								$ 500,000	$ 39,200,000

Dispositions, Deconsolidation_4

Dispositions, Deconsolidations and Discontinued Operations - Summarized Operating Results of the Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on sale and liquidation of subsidiaries				$ (159.9)
Loss from discontinued operations, net of tax and noncontrolling interest	$ 0	$ (200.3)	$ 0	(149)
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	0	0	0	1.7
Life, accident and health earned premiums, net	0	0	0	55.7
Net investment income	0	0	0	92.4
Realized/unrealized gains on investments	0	0	0	5.1
Total revenue	0	0	0	154.9
Cost of revenue	0	0	0	0.8
Policy benefits, changes in reserves, and commissions	0	0	0	126
Selling, general and administrative	0	0	0	21.1
Depreciation and amortization	0	0	0	(11)
Income from operations	0	0	0	18
Interest expense	0	0	0	(0.5)
Loss on sale and liquidation of subsidiaries	0	(200.3)	0	(159.9)
Other loss	0	0	0	(3.1)
Pre-tax loss from discontinued operations	0	(200.3)	0	(145.5)
Income tax expense	0	0	0	(4.4)
Loss from discontinued operations, net of tax and noncontrolling interest	$ 0	$ (200.3)	$ 0	$ (149.9)

Leases - Right-of-use Assets an

Leases - Right-of-use Assets and Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Right-of-use assets:
Operating lease (Other assets)	$ 65.7	$ 69.6
Finance lease (Property, plant and equipment, net)	2.2	0.2
Total right-of-use assets	67.9	69.8
Lease liabilities:
Current portion of operating lease (Other current liabilities)	17.3	15.5
Non-current portion of operating lease (Other liabilities)	53.2	58.5
Finance lease (Debt obligations)	2.2	0.1
Total lease liabilities	$ 72.7	$ 74.1
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Debt obligations	Debt obligations

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Finance lease cost:
Amortization of right-of-use assets	$ 0.1	$ 0.2	$ 0.2	$ 0.8
Interest on lease liabilities	0	0	0	0
Net finance lease cost	0.1	0.2	0.2	0.8
Operating lease cost	5.8	7.9	17.6	15.7
Variable lease cost	0.1	0.1	0.4	0.3
Sublease income	(0.1)	0	(0.5)	0
Total lease cost	$ 5.9	$ 8.2	$ 17.7	$ 16.8

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Financing cash flows from finance leases	$ 0	$ 0.1	$ 0.1	$ 0.6
Operating cash flows from operating leases	5.6	8.1	17.6	16
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases	1.7	0	2.2	0
Operating leases	$ 2.8	$ 1.7	$ 10.5	$ 42.9

Leases - Weighted Average Remai

Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (years) - operating lease	7 years 6 months	7 years 6 months
Weighted-average remaining lease term (years) - finance lease	1 year 7 months 6 days	2 years 3 months 18 days
Weighted-average discount rate - operating lease (as percent)	5.40%	5.40%
Weighted-average discount rate - finance lease (as percent)	5.60%	4.20%

Leases - Future Payments of Lea

Leases - Future Payments of Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
2022	$ 5.1
2023	19.2
2024	13.4
2025	10
2026	6.8
Thereafter	31.6
Total future lease payments	86.1
Less: Present values	(15.6)
Total lease liability balance	70.5
Finance Leases
2022	0.1
2023	1.8
2024	0.3
2025	0.1
2026	0
Thereafter	0
Total minimum principal and interest payments	2.3
Less: Present values	(0.1)
Total lease liability balance	$ 2.2	$ 0.1

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	1 Months Ended
	Dec. 31, 2021 USD ($) ft²	Nov. 30, 2021 USD ($) ft²
West Palm Beach, Florida, Lease Commencing November 2023
Lessee, Lease, Description [Line Items]
Lease not yet commenced, term of contract		10 years
Monthly lease payments		$ 200
Maintenance charges		$ 600
Percentage of annual adjustment in lease payment and charges		3%
Area of land leased, not yet commenced | ft²		20,950
Lease not yet commenced allowance receivable		$ 2,100
West Palm Beach, Florida, Lease Commencing Fourth Quarter 2023
Lessee, Lease, Description [Line Items]
Lease not yet commenced, term of contract	5 years
Monthly lease payments	$ 140
Percentage of annual adjustment in lease payment and charges	3%
Area of land leased, not yet commenced | ft²	15,786
Lease not yet commenced, renewal term	5 years

Other Assets (Details)

Other Assets (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Right-of-use assets	$ 65.7	$ 69.6
Restricted cash - non-current	1.5	0	$ 0	$ 0
Other	4.2	3.7
Total other assets	71.4	$ 73.3
Impairment of the right-of-use asset	$ 0.4

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued expenses and other current liabilities	$ 21.7	$ 24.5
Accrued payroll and employee benefits	40.4	38.9
Accrued interest	25.8	29.6
Accrued income taxes	0.3	0.4
Total accrued liabilities	$ 88.2	$ 93.4

Debt Obligations - Schedule of

Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Millions		9 Months Ended
	Feb. 23, 2021	Sep. 30, 2022	Dec. 31, 2021	Feb. 01, 2021
Debt Instrument [Line Items]
Obligations under finance leases		$ 2.2	$ 0.1
Total aggregate finance lease and debt payments		711.5	630.8
Unamortized issuance discount, issuance premium, and deferred financing costs		(2.2)	(4.5)
Less: current portion of debt obligations		(81.4)	(69.5)
Debt obligations		627.9	556.8
8.50% Senior Secured Notes, due 2026
Debt Instrument [Line Items]
Interest rate				100%
Infrastructure
Debt Instrument [Line Items]
Obligations under finance leases		2.2	0.1
Infrastructure | 3.25% Note due 2026 | Real Estate Term Advance
Debt Instrument [Line Items]
Outstanding debt		$ 101	107.2
Infrastructure | 3.25% Note due 2026 | Real Estate Term Advance | DBM Global Credit Facilities | Revolving Credit Facility
Debt Instrument [Line Items]
Interest rate		3.25%
Infrastructure | PRIME minus 0.85% Line of Credit due 2024 | Real Estate Term Advance
Debt Instrument [Line Items]
Outstanding debt		$ 107.7	30.4
Infrastructure | 4.00% Note due 2024 | Real Estate Term Advance
Debt Instrument [Line Items]
Interest rate		4%
Outstanding debt		$ 17.5	25
Infrastructure | 8.00% Note due 2024 | Real Estate Term Advance
Debt Instrument [Line Items]
Interest rate		8%
Outstanding debt		$ 19.1	19.6
Infrastructure | 11.00% Note due 2024 | Real Estate Term Advance
Debt Instrument [Line Items]
Interest rate		11%
Outstanding debt		$ 0	6.3
Infrastructure | Prime Rate | PRIME minus 0.85% Line of Credit due 2024 | Real Estate Term Advance | DBM Global Credit Facilities | Revolving Credit Facility
Debt Instrument [Line Items]
Basis spread on variable rate		0.85%
Spectrum | 8.50% Note due 2022
Debt Instrument [Line Items]
Interest rate		8.50%
Outstanding debt		$ 19.3	19.3
Spectrum | 10.50% Note due 2022
Debt Instrument [Line Items]
Interest rate		10.50%
Outstanding debt		$ 32.9	32.9
Life Sciences | 12.00% Note due 2022
Debt Instrument [Line Items]
Interest rate		12%
12.00% Note due 2022		$ 10	0
Non-Operating Corporate | 8.50% Senior Secured Notes, due 2026
Debt Instrument [Line Items]
Interest rate		8.50%		8.50%
Outstanding debt		$ 330	330
Non-Operating Corporate | 7.50% Convertible Senior Notes, due 2026
Debt Instrument [Line Items]
Interest rate		7.50%
Outstanding debt		$ 51.8	51.8
Non-Operating Corporate | 7.50% Convertible Senior Notes, due 2022
Debt Instrument [Line Items]
Interest rate		7.50%		7.50%
Outstanding debt		$ 0	3.2
Non-Operating Corporate | LIBOR plus 5.75% Line of Credit due 2024
Debt Instrument [Line Items]
Basis spread on variable rate	6.75%
Outstanding debt		$ 20	$ 5
Non-Operating Corporate | LIBOR | LIBOR plus 5.75% Line of Credit due 2024
Debt Instrument [Line Items]
Basis spread on variable rate		5.75%

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Aggregate Debt Maturities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Finance Leases
2022	$ 0.1
2023	1.8
2024	0.3
2025	0.1
2026	0
Thereafter	0
Total minimum principal and interest payments	2.3
Less: Amount representing interest	(0.1)
Total lease liability balance	2.2	$ 0.1
Debt
2022	79.2
2023	62.3
2024	194.2
2025	41.2
2026	469.8
Thereafter	0
Total minimum principal and interest payments	846.7
Less: Amount representing interest	(137.4)
Total aggregate finance lease and debt payments	709.3
Total
2022	79.3
2023	64.1
2024	194.5
2025	41.3
2026	469.8
Thereafter	0
Total minimum principal and interest payments	849
Less: Amount representing interest	(137.5)
Total aggregate finance lease and debt payments	$ 711.5	$ 630.8

Debt Obligations - Infrastructu

Debt Obligations - Infrastructure and Spectrum Narrative (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

Oct. 26, 2021

Oct. 21, 2021

Aug. 30, 2021

Oct. 24, 2019

May 31, 2021

Dec. 31, 2020

Nov. 30, 2020

Sep. 30, 2020

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Aug. 02, 2022

Aug. 01, 2022

Aug. 31, 2020

Feb. 29, 2020

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 0

$ (100,000)

$ 0

$ (12,500,000)

Proceeds from debt obligations, net of deferred financing costs

9,900,000

452,300,000

Repayments of long-term debt

$ 23,700,000

$ 454,800,000

Spectrum

Debt Instrument [Line Items]

Number of warrants outstanding (in shares)

50,000

Exercise price of warrants (in usd per share)

$ 176.4

Value of warrants issued

$ 8,800,000

Term of warrants outstanding

5 years

Senior Notes Due October2020 8.5% | Spectrum

Debt Instrument [Line Items]

12.00% Note due 2022

$ 78,700,000

Debt instrument, term

364 days

Tranche A Senior Notes Due October2020 | Spectrum

Debt Instrument [Line Items]

Face amount

$ 43,300,000

$ 39,300,000

Interest rate

8.50%

8.50%

8.50%

8.50%

8.50%

8.50%

12.00% Note due 2022

$ 36,200,000

Proceeds from debt obligations, net of deferred financing costs

$ 4,000,000

Repayments of long-term debt

$ 21,000,000

$ 2,900,000

Tranche B Senior Notes Due October2020 | Spectrum

Debt Instrument [Line Items]

Interest rate

10.50%

10.50%

10.50%

12.00% Note due 2022

$ 42,500,000

Repayments of long-term debt

$ 9,600,000

Other, various maturity dates | Spectrum

Debt Instrument [Line Items]

Repayments of long-term debt

$ 3,000,000

DTV America’s Secured Notes | Spectrum

Debt Instrument [Line Items]

Repurchased outstanding notes payable

$ 6,200,000

DTV America’s Secured Notes | Spectrum | Sellers' Notes

Debt Instrument [Line Items]

Repurchased outstanding notes payable

$ 1,000,000

Term extension period

60 days

Senior Secured Notes Due November 30, 2022 | Spectrum | Senior Notes

Debt Instrument [Line Items]

Face amount

$ 52,200,000

DTV America’s Convertible Promissory Notes | Spectrum | Convertible Notes Payable

Debt Instrument [Line Items]

Repurchased outstanding notes payable

$ 700,000

Revolving Credit Facility | Infrastructure

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 1,600,000

Revolving Credit Facility | Infrastructure | UMB Bank

Debt Instrument [Line Items]

Line of credit, maximum amount

$ 110,000,000

Interest rate

3.25%

Interest rate, effective percentage

3.25%

Revolving Credit Facility | LIBOR plus 1.50% Line of Credit | Infrastructure | Real Estate Term Advance | LIBOR | DBM Global Credit Facilities

Debt Instrument [Line Items]

Basis spread on variable rate

1.50%

Term Loan | Infrastructure | UMB Bank

Debt Instrument [Line Items]

Face amount

$ 110,000,000

Line of credit, maximum amount

$ 135,000,000

$ 110,000,000

Minimum

Debt Instrument [Line Items]

Finance leases rate

2%

Maximum

Debt Instrument [Line Items]

Finance leases rate

6%

Debt Obligations - Life Science

Debt Obligations - Life Sciences Narrative (Details) - Life Sciences $ in Millions				3 Months Ended	9 Months Ended
	Aug. 08, 2022 USD ($)	Jul. 13, 2022 USD ($) security	Jun. 27, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Affiliated Entity
Debt Instrument [Line Items]
Repurchased outstanding notes payable		$ 4.5
Return from equity or debt financing, minimum		10
Interest cost relating to contractual interest coupon				$ 0.2	$ 0.2
12.00% Note due 2022
Debt Instrument [Line Items]
Interest rate				12%	12%
12.00% Note due 2022 | Affiliated Entity | Bridge Loan
Debt Instrument [Line Items]
Face amount			$ 0.5
Debt instrument, term			90 days
Interest rate			12%
Repayments of related party debt		$ 0.5
Sellers' Notes | Affiliated Entity | R2 Technologies
Debt Instrument [Line Items]
Related party transaction, rate		12%
Number of tranches | security		2
Notes Payable Tranche One | Affiliated Entity
Debt Instrument [Line Items]
Repurchased outstanding notes payable		$ 5
Notes Payable Second Tranche | Affiliated Entity
Debt Instrument [Line Items]
Repurchased outstanding notes payable	$ 5

Debt Obligations - Non-Operatin

Debt Obligations - Non-Operating Corporate Narrative (Details) - USD ($)				1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 01, 2022	Feb. 23, 2021	Feb. 01, 2021	Aug. 03, 2022	May 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Repayments of long-term debt								$ 23,700,000	$ 454,800,000
Loss on extinguishment of debt						$ 0	$ 100,000	0	12,500,000
Proceeds from line of credit, net of deferred financing costs								176,800,000	156,000,000
8.50% Senior Secured Notes, due 2026
Debt Instrument [Line Items]
Interest rate			100%
Interest rate, effective percentage			9.26%
Deferred financing cost			$ 2,700,000
8.50% Senior Secured Notes, due 2026 | Convertible Debt
Debt Instrument [Line Items]
Amortization of discount (premium) on investments, net								22,600,000
Interest cost relating to contractual interest coupon								$ 22,600,000	19,700,000
8.50% Senior Secured Notes, due 2026 | Non-Operating Corporate
Debt Instrument [Line Items]
Repayments of long-term debt			$ 330,000,000
Interest rate			8.50%			8.50%		8.50%
7.50% Convertible Senior Notes, due 2022 | Convertible Debt
Debt Instrument [Line Items]
Repayments of long-term debt	$ 3,200,000
Amortization of discount (premium) on investments, net								$ 300,000	300,000
Interest cost relating to contractual interest coupon								$ 200,000	200,000
7.50% Convertible Senior Notes, due 2022 | Non-Operating Corporate
Debt Instrument [Line Items]
Repayments of long-term debt			$ 55,000,000
Interest rate			7.50%			7.50%		7.50%
Face amount			$ 51,800,000
Loss on extinguishment of debt			5,500,000
Amortization of discount (premium) on investments, net			5,300,000
Extinguishment of the bifurcated conversion option equity			7,700,000
Senior Notes Due 2021, 11.5% | Non-Operating Corporate
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 4,500,000
7.50% Convertible Senior Notes, due 2026
Debt Instrument [Line Items]
Amortization of discount (premium) on investments, net								$ 1,500,000	(1,300,000)
Long-term debt, gross						$ 59,800,000		$ 59,800,000
Share price (in usd per share)						$ 0.70		$ 0.70
Interest cost relating to contractual interest coupon								$ 1,500,000	$ 1,300,000
Unamortized premium						$ 8,800,000		$ 8,800,000
7.50% Convertible Senior Notes, due 2026 | Non-Operating Corporate
Debt Instrument [Line Items]
Interest rate						7.50%		7.50%
LIBOR plus 5.75% Line of Credit due 2024 | Non-Operating Corporate
Debt Instrument [Line Items]
Basis spread on variable rate		6.75%
LIBOR plus 5.75% Line of Credit due 2024 | Non-Operating Corporate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		5.75%
LIBOR plus 5.75% Line of Credit due 2024 | Non-Operating Corporate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		6.75%
Revolving Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Face amount		$ 20,000,000
Proceeds from line of credit, net of deferred financing costs				$ 15,000,000	$ 5,000,000

Other Liabilities (Details)

Other Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Lease liability, net of current portion	$ 53.2	$ 58.5
Other	4.4	4.8
Total other liabilities	$ 57.6	$ 63.3

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Income tax expense	$ (2)	$ 0.1	$ 1.6	$ 3.8
Operating loss carryforwards, US	170.9		170.9
Reduced deferred tax asset carryforward					$ 58.7
CGI | Discontinued Operations | CIG
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 2.9		$ 2.9
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards					239.6
Domestic Tax Authority | CGI | Discontinued Operations | CIG
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards					75.1
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Foreign operating loss carryforward					103.9
Foreign Tax Authority | R2 Technologies
Operating Loss Carryforwards [Line Items]
Foreign operating loss carryforward					66.1
Foreign Tax Authority | DTV America
Operating Loss Carryforwards [Line Items]
Foreign operating loss carryforward					33.5
Foreign Tax Authority | Other Entities
Operating Loss Carryforwards [Line Items]
Foreign operating loss carryforward					$ 4.3

Commitments and Contingencies (

Commitments and Contingencies (Details) € in Millions, $ in Millions	Jun. 24, 2022	Mar. 15, 2021 plaintiff	Oct. 30, 2019 security	Oct. 28, 2022 USD ($) license station	Sep. 30, 2022 USD ($) claim	Aug. 01, 2022 EUR (€)	Aug. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 13, 2020	May 12, 2020
Loss Contingencies [Line Items]
Sale of equity interest, number of tranches | security			2
Frank Digital Acquisition | Subsequent Event
Loss Contingencies [Line Items]
Estimate of possible loss				$ 0.1
Gray Media Sale | Subsequent Event
Loss Contingencies [Line Items]
Estimate of possible loss				$ 0.5
Number of licenses sold | license				6
Sale Of Stations | Subsequent Event
Loss Contingencies [Line Items]
Number of stations sold | station				2
Sale Of Station One | Subsequent Event
Loss Contingencies [Line Items]
Estimate of possible loss				$ 0.2
Sale Of Station Two | Subsequent Event
Loss Contingencies [Line Items]
Estimate of possible loss				0.4
TV-49, Licences, Breach Of Fiduciary Duty | Subsequent Event
Loss Contingencies [Line Items]
Estimate of possible loss				$ 0.1
HMRC
Loss Contingencies [Line Items]
VAT refunds						€ 1.1	$ 1.3
DBMG | Credit And Security Agreements
Loss Contingencies [Line Items]
Letters of credit outstanding					$ 2.6			$ 13.5
DBMG | Performance Bonds
Loss Contingencies [Line Items]
Letters of credit outstanding					$ 1,057.8			$ 900.8
Huawei Marine Networks
Loss Contingencies [Line Items]
Ownership percentage before sale of stock	19%		49%
Onwerhsip interest			49%						19%	30%
Fair Value Investments Incorporated
Loss Contingencies [Line Items]
Number of remaining claims in discovery | claim					2
DTV America Corporation Stockholders
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff		22
DTV America Corporation Stock Option Holders
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff		8

Share-based Compensation - Narr

Share-based Compensation - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 400,000	$ 400,000	$ 1,700,000	$ 1,700,000
Weighted average fair value at date of grant for options granted (in usd per share)			$ 1.47
Intrinsic value of options outstanding	$ 0		$ 0
Average remaining life of option outstanding			2 years 1 month 6 days
Maximum contractual term of company's exercisable options			10 years
Unvested stock options (in shares)	0		0
Unrecognized stock-based compensation expenses related to unvested stock options	$ 0		$ 0
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period (in years)			2 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period (in years)			3 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate fair value of restricted common stock vested			$ 800,000
Unrecognized compensation expense	$ 2,200,000		$ 2,200,000
Unrecognized compensation expense, period for recognition			2 years 2 months 12 days

Share-based Compensation - Summ

Share-based Compensation - Summary of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Shares
Unvested at beginning of period (in shares)	555,879	628,433
Granted (in shares)	599,797	593,458
Vested (in shares)	(292,091)	(514,543)
Forfeited (in shares)	(45,289)	(151,469)
Unvested at end of period (in shares)	818,296	555,879
Weighted Average Grant Date Fair Value
Unvested at beginning of period (in usd per share)	$ 3.79	$ 3.93
Granted (in usd per share)	3.57	3.81
Vested (in usd per share)	3.81	3.89
Forfeited (in usd per share)	3.68	4.13
Unvested at end of period (in usd per share)	$ 3.63	$ 3.79

Share-based Compensation - Su_2

Share-based Compensation - Summary of Company's Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Shares
Outstanding at beginning of period (in shares)	4,715,859	4,739,858
Granted (in shares)	280,791
Exercised (in shares)	0
Forfeited (in shares)	0
Expired (in shares)	(1,500)	(23,999)
Outstanding at end of period (in shares)	4,995,150	4,715,859
Shares, Eligible for exercise (in shares)	4,995,150
Weighted Average Exercise Price
Outstanding at beginning of period (in usd per share)	$ 5.13	$ 5.13
Granted (in usd per share)	3.25
Exercised (in usd per share)	0
Forfeited (in usd per share)	0
Expired (in usd per share)	4.06	5.31
Outstanding at end of period (in usd per share)	5.02	$ 5.13
Weighted average exercise price, Eligible for exercise (in usd per share)	$ 5.02

Temporary Equity - Preferred St

Temporary Equity - Preferred Stock (Details) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Par value (in usd per share)	$ 0.001	$ 0.001
Preferred shares authorized (in shares)	20,000,000	20,000,000
Series A- 3 Preferred Stock
Class of Stock [Line Items]
Shares issued (in shares)	6,125	6,125
Shares outstanding (in shares)	6,125	6,125
Series A- 4 Preferred Stock
Class of Stock [Line Items]
Shares issued (in shares)	10,000	10,000
Shares outstanding (in shares)	10,000	10,000

Temporary Equity - Narrative (D

Temporary Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			9 Months Ended
	Jul. 01, 2021	Nov. 30, 2018	Sep. 30, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Proceed from exchange for accrued and unpaid dividend	$ 0.3
Preferred stock			$ 17.9	$ 18.8
Preferred stock cumulative cash dividend rate			7.50%
Preferred stock dividend rate			4%
Accreting dividend threshold rate			7.25%
Volume weighted average price threshold percentage			150%
Preferred stock force conversion, trading days to calculate volume weighted average price			30 days
Preferred stock trading days to calculate volume weighted average price (at least)			20 days
Consent rights percentage (at least)			75%
Maximum
Class of Warrant or Right [Line Items]
Preferred stock dividend rate			2%
Minimum
Class of Warrant or Right [Line Items]
Preferred stock dividend rate			0%
Series A shares issued and outstanding
Class of Warrant or Right [Line Items]
Preferred stock conversion price (in usd per share)			$ 3.52
Series A-2 shares issued and outstanding
Class of Warrant or Right [Line Items]
Preferred stock conversion price (in usd per share)			5.33
Series A-3 Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock conversion price (in usd per share)			$ 4.25
Number of shares to be issued upon conversion of preferred stock (in shares)			1,740,700
Series A-4 Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock conversion price (in usd per share)			$ 8.25
Number of shares to be issued upon conversion of preferred stock (in shares)			1,875,533
CGI
Class of Warrant or Right [Line Items]
Redemption value	$ 16.1
CGI | Series A shares issued and outstanding
Class of Warrant or Right [Line Items]
Shares issued (in shares)	6,125
CGI | Series A-2 shares issued and outstanding
Class of Warrant or Right [Line Items]
Issuance and sale of common stock (in shares)	10,000
DBMGi
Class of Warrant or Right [Line Items]
Preferred stock, dividend, paid in kind percentage			9%
Preferred stock, dividend paid in cash, percentage			8.25%
DBMGi | LIBOR
Class of Warrant or Right [Line Items]
Preferred stock, dividend, basis spread on variable rate			5.85%
DBMGi | Paid In Kind
Class of Warrant or Right [Line Items]
Preferred stock, dividend, basis spread on variable rate			0.75%
DBMGi | Series A shares issued and outstanding | Discontinued Operations | CIG
Class of Warrant or Right [Line Items]
Issued in disposal group	$ 40.9
DBMGi | Series A shares issued and outstanding | Consolidation, Eliminations
Class of Warrant or Right [Line Items]
Issuance and sale of common stock (in shares)		40,000

Temporary Equity - Summary of C

Temporary Equity - Summary of Cash Dividends (Details) - USD ($) $ in Millions

3 Months Ended

9 Months Ended

Oct. 15, 2022

Jul. 15, 2022

Apr. 15, 2022

Oct. 15, 2021

Jun. 04, 2021

Apr. 15, 2021

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Sep. 30, 2022

Sep. 30, 2021

Class of Stock [Line Items]

Total Dividend

$ 0.3

$ 0.3

$ 0.3

$ 0.3

$ 0.1

$ 0.2

Dividend payments

$ 3.9

$ 2

Preferred stock

Class of Stock [Line Items]

Dividend payments

$ 0.3

$ 0.3

$ 0.3

$ 0.1

$ 0.2

Preferred stock | Subsequent Event

Class of Stock [Line Items]

Dividend payments

$ 0.3

DBMGi

Class of Stock [Line Items]

Total Dividend

$ 0.9

$ 0.9

$ 0.9

$ 0.8

DBMGi | Preferred stock

Class of Stock [Line Items]

Dividend payments

$ 0.9

$ 0.9

$ 0.8

DBMGi | Preferred stock | Subsequent Event

Class of Stock [Line Items]

Dividend payments

$ 0.9

Related Parties (Details)

Related Parties (Details)					1 Months Ended	3 Months Ended			9 Months Ended
	Aug. 08, 2022 USD ($)	Jul. 13, 2022 USD ($) security	Jun. 27, 2022 USD ($)	Apr. 04, 2022 USD ($)	Sep. 30, 2018	Sep. 30, 2022 USD ($)	Mar. 31, 2022 plane	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) office_space plane	Sep. 30, 2021 USD ($)	May 27, 2021 USD ($)
Related Party Transaction [Line Items]
Lease term					75 months
Operating cash flows from operating leases						$ 5,600,000		$ 8,100,000	$ 17,600,000	$ 16,000,000
Total lease liability balance						70,500,000			70,500,000
Share-based compensation expense						$ 400,000		400,000	$ 1,700,000	1,700,000
12.00% Note due 2022 | Life Sciences
Related Party Transaction [Line Items]
Interest rate						12%			12%
Banker Steel Acquisition
Related Party Transaction [Line Items]
Bankers Steel debt - assumed											$ 6,300,000
Affiliated Entity | Life Sciences
Related Party Transaction [Line Items]
Repurchased outstanding notes payable		$ 4,500,000
Return from equity or debt financing, minimum		10,000,000
Interest cost relating to contractual interest coupon						$ 200,000			$ 200,000
Affiliated Entity | 12.00% Note due 2022 | Life Sciences | Bridge Loan
Related Party Transaction [Line Items]
Face amount			$ 500,000
Debt instrument, term			90 days
Interest rate			12%
Repayments of related party debt		500,000
Affiliated Entity | Notes Payable Tranche One | Life Sciences
Related Party Transaction [Line Items]
Repurchased outstanding notes payable		$ 5,000,000
Affiliated Entity | Notes Payable Second Tranche | Life Sciences
Related Party Transaction [Line Items]
Repurchased outstanding notes payable	$ 5,000,000
Affiliated Entity | Banker Steel Acquisition | Subordinated Debt
Related Party Transaction [Line Items]
Subordinated borrowing, interest rate				11%
Banker Steel | Office Space | Affiliated Entity
Related Party Transaction [Line Items]
Number of office spaces | office_space									2
Operating cash flows from operating leases									$ 10,000
Total lease liability balance						100,000			100,000
Lease expense						24,000		23,000	72,000	31,000
Banker Steel | Planes | Affiliated Entity
Related Party Transaction [Line Items]
Operating cash flows from operating leases									100,000
Total lease liability balance						1,600,000			1,600,000
Lease expense						300,000		400,000	$ 1,000,000	600,000
Number of planes leased | plane							2		1
Number of planes terminated | plane							1
Donald Banker | Affiliated Entity | Subordinated Debt
Related Party Transaction [Line Items]
Interest expense						0		$ 100,000	$ 200,000	$ 200,000
Donald Banker | Affiliated Entity | Banker Steel Acquisition | Subordinated Debt
Related Party Transaction [Line Items]
Bankers Steel debt - assumed				$ 6,300,000
R2 Technologies | Affiliated Entity
Related Party Transaction [Line Items]
Royalty expense						$ 100,000
Share-based compensation expense									$ 300,000
R2 Technologies | Affiliated Entity | Sellers' Notes | Life Sciences
Related Party Transaction [Line Items]
Related party transaction, rate		12%
Number of tranches | security		2

Operating Segments and Relate_3

Operating Segments and Related Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of reportable geographic segments	1
Number of reportable operating segments	3

Operating Segments and Relate_4

Operating Segments and Related Information - Concentration of Risk, by Risk Factor (Details) - Sales Revenue, Net - Customer Concentration Risk - Infrastructure	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Customer A
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk, percentage	25.20%	18.90%	24.20%	12.20%
Customer B
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk, percentage		13%
Customer C
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk, percentage	10.10%

Operating Segments and Relate_5

Operating Segments and Related Information - Operating Segments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 423	$ 394.8	$ 1,228	$ 810.4
Total Infrastructure segment revenue	423	394.8	1,228	810.4
Income (loss) from operations	6.6	1.1	6.9	(17.5)
Interest expense	(13.3)	(12.8)	(38.4)	(46.6)
Loss on early extinguishment or restructuring of debt	0	(0.1)	0	(12.5)
Loss from equity investees	(1.1)	(2.9)	(2.1)	(4.8)
Other (expense) income, net	(0.9)	0.6	0.5	4.4
Loss from continuing operations before income taxes	(8.7)	(14.1)	(33.1)	(77)
Depreciation and Amortization	6.8	8.9	20.6	17.6
Total depreciation and amortization	10.7	12.3	31.8	26
Capital Expenditures	7.5	7	16.3	15
Infrastructure
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	412.6	383	1,196.6	776.3
Total Infrastructure segment revenue	412.7	383	1,197	776.3
Life Sciences
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	1.2	1.6	3	2.8
Spectrum
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	9.1	10.2	28	31.3
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation and Amortization	9.2	10.8	27.1	21.5
Infrastructure recognized within cost of revenue	3.9	3.4	11.2	8.4
Operating Segments | Infrastructure
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	412.7	383	1,197	776.3
Income (loss) from operations	18.5	12.6	42.2	17
Depreciation and Amortization	5.3	7.4	15.9	13.1
Capital Expenditures	6.9	6.1	13.5	11.6
Operating Segments | Life Sciences
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	1.2	1.6	3	2.8
Income (loss) from operations	(5.5)	(4.9)	(15.7)	(14.2)
Depreciation and Amortization	0.1	0	0.2	0.1
Capital Expenditures	0.2	0	0.3	0.5
Operating Segments | Spectrum
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	9.1	10.2	28	31.3
Income (loss) from operations	(0.6)	(1.2)	(4.1)	(1)
Depreciation and Amortization	1.4	1.4	4.4	4.3
Capital Expenditures	0.4	0.9	2.5	2.9
Operating Segments | Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Income (loss) from operations	(0.3)	(1)	(0.4)	(1.6)
Non-operating Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Income (loss) from operations	(5.5)	(4.4)	(15.1)	(17.7)
Depreciation and Amortization	$ 0	$ 0.1	$ 0.1	$ 0.1

Operating Segments and Relate_6

Operating Segments and Related Information - Long-term investments, Property and Equipment and Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Investments	$ 57.7	$ 56
Equity Method Investments (included in Investments above)	40.8	38.8
Assets	1,165.2	1,080.6
Operating Segments | Infrastructure
Revenues from External Customers and Long-Lived Assets [Line Items]
Investments	0	0.7
Equity Method Investments (included in Investments above)	0	0.7
Assets	893.3	786.4
Operating Segments | Life Sciences
Revenues from External Customers and Long-Lived Assets [Line Items]
Investments	9	10.2
Equity Method Investments (included in Investments above)	3.4	4.2
Assets	18.8	22
Operating Segments | Spectrum
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets	191	198.9
Operating Segments | Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Investments	48.7	45.1
Equity Method Investments (included in Investments above)	37.4	33.9
Assets	50.4	48
Non-operating Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets	$ 11.7	$ 25.3

Basic and Diluted Loss Per Co_3

Basic and Diluted Loss Per Common Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Antidilutive securities (in shares)	0	0	0	0

Basic and Diluted Loss Per Co_4

Basic and Diluted Loss Per Common Share - Basic Income (Loss) Per Common Share to Diluted Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Loss from continuing operations	$ (6.7)	$ (14.2)	$ (34.7)	$ (80.8)
Loss from continuing operations attributable to noncontrolling interest and redeemable noncontrolling interest	1.3	2.6	4.5	7
Loss from continuing operations attributable to INNOVATE Corp.	(5.4)	(11.6)	(30.2)	(73.8)
Less: Preferred dividends and deemed dividends from conversions	1.2	1.1	3.6	1.7
Loss from continuing operations attributable to INNOVATE common stockholders	(6.6)	(12.7)	(33.8)	(75.5)
Less: Loss from discontinued operations, net of tax	0	(200.3)	0	(149.9)
Loss from discontinued operations attributable to noncontrolling interest and redeemable noncontrolling interest	0	0	0	0.9
Loss from discontinued operations, net of tax and noncontrolling interest	0	(200.3)	0	(149)
Net loss attributable to common stock and participating preferred stockholders	$ (6.6)	$ (213)	$ (33.8)	$ (224.5)
Participating shares at end of period:
Weighted-average common stock outstanding (in shares)	77.6	77.2	77.5	77
Unvested restricted stock (in shares)	0	0	0	0
Preferred stock (as-converted basis) (in shares)	0	0	0	0
Total (in shares)	77.6	77.2	77.5	77
Percentage of loss allocated to:
Common stock (as percent)	100%	100%	100%	100%
Unvested restricted stock (as percent)	0%	0%	0%	0%
Preferred stock (as percent)	0%	0%	0%	0%
Net loss from continuing operations attributable to common stock, basic	$ (6.6)	$ (12.7)	$ (33.8)	$ (75.5)
Net loss from discontinued operations attributable to common stock, basic	0	(200.3)	0	(149)
Net loss attributable to common stock, basic	(6.6)	(213)	(33.8)	(224.5)
Earnings allocable to common shares, diluted:
Net loss from continuing operations attributable to common stock, basic	(6.6)	(12.7)	(33.8)	(75.5)
Net loss from discontinued operations attributable to common stock, basic	0	(200.3)	0	(149)
Net loss attributable to common stock, basic	$ (6.6)	$ (213)	$ (33.8)	$ (224.5)
Denominator for basic and dilutive loss per share
Weighted average common shares outstanding - basic (in shares)	77.6	77.2	77.5	77
Effect of assumed shares under treasury stock method for stock options and restricted shares and if-converted method for convertible instruments (in shares)	0	0	0	0
Weighted average common shares outstanding - diluted (in shares)	77.6	77.2	77.5	77
Loss per share - continuing operations
Basic (in usd per share)	$ (0.09)	$ (0.16)	$ (0.44)	$ (0.98)
Diluted (in usd per share)	(0.09)	(0.16)	(0.44)	(0.98)
Loss per share - discontinued operations
Basic (in usd per share)	0	(2.59)	0	(1.94)
Diluted (in usd per share)	0	(2.59)	0	(1.94)
Loss per share - Net loss attributable to common stock and participating preferred stockholders
Basic (in usd per share)	(0.09)	(2.75)	(0.44)	(2.92)
Diluted (in usd per share)	$ (0.09)	$ (2.75)	$ (0.44)	$ (2.92)

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Financial Instruments Measured on Not Measured at Fair Value (Details) - Nonrecurring - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Carrying Value
Assets
Other invested assets	$ 11.3	$ 11.3
Total assets not accounted for at fair value	11.3	11.3
Liabilities
Debt obligations	707.1	626.3
Total liabilities not accounted for at fair value	707.1	626.3
Estimated Fair Value
Assets
Other invested assets	11.3	11.3
Total assets not accounted for at fair value	11.3	11.3
Liabilities
Debt obligations	637.5	648.2
Total liabilities not accounted for at fair value	637.5	648.2
Estimated Fair Value | Level 1
Assets
Other invested assets	0	0
Total assets not accounted for at fair value	0	0
Liabilities
Debt obligations	0	0
Total liabilities not accounted for at fair value	0	0
Estimated Fair Value | Level 2
Assets
Other invested assets	0	0
Total assets not accounted for at fair value	0	0
Liabilities
Debt obligations	637.5	648.2
Total liabilities not accounted for at fair value	637.5	648.2
Estimated Fair Value | Level 3
Assets
Other invested assets	11.3	11.3
Total assets not accounted for at fair value	11.3	11.3
Liabilities
Debt obligations	0	0
Total liabilities not accounted for at fair value	$ 0	$ 0

Supplementary Financial Infor_3

Supplementary Financial Information - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Offsetting Assets [Line Items]
Cash and cash equivalents	$ 55.5	$ 25.8	$ 55.5	$ 45.5	$ 43.8
Restricted cash	8.6	0.4	8.6	2	1.5
Restricted cash - non-current	0	1.5	0	0	0
Total cash, cash equivalents and restricted cash	64.1	27.7	64.1	47.5	45.3
Cash paid for interest		38.9	31.3
Cash paid for taxes, net of refunds		3.8	4.3
Property, plant and equipment included in accounts payable		0.9	2.1
Issuance of preferred stock and nonredeemable controlling interest	40.9		40.9
Issuance of redeemable noncontrolling interest		0	40.9
Extinguishment of convertible note in exchange		0	51.8
Issuance of convertible note in exchange		0	(51.8)
Debt assumed in acquisitions		0	6.3
Preferred stock and fixed maturities
Offsetting Assets [Line Items]
Issuance of preferred stock and nonredeemable controlling interest	19.1	(0.9)	19.1
Discontinued Operations
Offsetting Assets [Line Items]
Cash and cash equivalents classified in Assets held for sale, beginning of period		0	195.2
Restricted cash classified in Assets held for sale	0	0	0	0	0.2
Total cash and cash equivalents and restricted cash classified in Assets held for sale	0	0	0	$ 0	$ 195.4
Cash and cash equivalents classified in Assets held for sale, end of period	$ 0	$ 0	$ 0